---

Complete Hepatology Across Subjects - Available Textbooks in the Library

---

MEDICINE (Internal Medicine)

Harrison's Principles of Internal Medicine, 22nd Edition (2025)

• ISBN: 9781265977061 | 56 blocks
• The gold standard for hepatology in medicine. Covers: viral hepatitis (A/B/C/D/E), autoimmune hepatitis, alcoholic liver disease, NAFLD/NASH, cirrhosis and its complications (portal hypertension, ascites, SBP, hepatic encephalopathy, hepatorenal syndrome, varices), primary biliary cholangitis, primary sclerosing cholangitis, Wilson's disease, hemochromatosis, alpha-1 antitrypsin deficiency, acute liver failure, hepatocellular carcinoma, liver transplantation, drug-induced liver injury (DILI), cholestatic diseases, and liver function tests.

Goldman-Cecil Medicine, 2-Volume Set (International Edition)

• ISBN: 9780323930345 | 59 blocks
• Comprehensive hepatology chapter coverage including hepatitis, cirrhosis, portal hypertension, cholestatic syndromes, metabolic liver diseases, and liver tumors.

The Washington Manual of Medical Therapeutics

• ISBN: 9781975190620 | 6 blocks
• Practical management of hepatitis, liver failure, and complications of cirrhosis (doses, protocols, when to refer).

Symptom to Diagnosis: An Evidence-Based Guide, 4th Edition

• ISBN: 9781260121117 | 6 blocks
• Approach to jaundice, abnormal LFTs, and ascites from a diagnostic reasoning perspective.

---

GASTROENTEROLOGY / GASTROSURGERY (Hepatology-dedicated books)

Sleisenger and Fordtran's Gastrointestinal and Liver Disease

• ISBN: 9780323609623 | 35 blocks
• The most comprehensive hepatology textbook in the library. Full coverage of every liver disease - the definitive reference for GI/liver pathology, management, and pharmacotherapy.

Yamada's Textbook of Gastroenterology, 3-Volume Set, 7th Edition

• ISBN: 9781119600169 | 30 blocks
• Extensive hepatology: viral hepatitis, chronic hepatitis, cirrhosis, liver tumors, metabolic liver disease, and liver transplantation.

Maingot's Abdominal Operations

• ISBN: 9780071639873 | 12 blocks
• Surgical hepatology: hepatectomy, liver resections, biliary surgery, portal hypertension surgery, shunt procedures.

---

SURGERY

Schwartz's Principles of Surgery, 11th Edition (2-volume)

• ISBN: 9781259835346 | 23 blocks
• Liver chapter: hepatic anatomy, liver resection, management of HCC, liver abscesses, hydatid cysts, portal hypertension, surgical management of varices, liver trauma.

Sabiston Textbook of Surgery, Biological Basis of Modern Surgical Practice

• ISBN: 9780443124341 | 30 blocks
• Hepatic surgery, biliary tract surgery, transplantation, liver tumors, surgical jaundice.

Bailey and Love's Short Practice of Surgery, 28th Edition

• ISBN: 9780367548117 | 13 blocks
• Surgical liver diseases: liver trauma, infections, tumors, biliary obstruction, portal hypertension. Hepatitis section included.

Fischer's Mastery of Surgery, 8th Edition

• ISBN: 9781975176433 | 30 blocks
• Advanced surgical hepatology and hepatopancreatobiliary (HPB) surgery techniques.

Current Surgical Therapy, 14th Edition

• ISBN: 9780323796835 | 17 blocks
• Current evidence-based surgical management of liver conditions.

---

PATHOLOGY

Robbins & Cotran Pathologic Basis of Disease (Full Edition)

• ISBN: 9780443264528 | 13 blocks
• The definitive pathology reference for hepatology. Full liver chapter with: normal liver histology, hepatitis (all types), alcoholic liver disease, NAFLD, cirrhosis (macro/micro nodular), hepatocellular carcinoma, cholangiocarcinoma, biliary atresia, Wilson's disease, hemochromatosis, alpha-1 AT deficiency, hepatic vein thrombosis (Budd-Chiari), primary biliary cholangitis, primary sclerosing cholangitis. Rich histopathology images.

Robbins & Kumar Basic Pathology

• ISBN: 9780323790185 | 8 blocks
• Condensed version of the same liver chapter - ideal for exam review of hepatology pathology.

---

PHARMACOLOGY

Goodman & Gilman's The Pharmacological Basis of Therapeutics

• ISBN: 9781264258079 | 21 blocks
• Drugs for viral hepatitis (interferons, direct-acting antivirals - sofosbuvir, ledipasvir, daclatasvir, ribavirin, lamivudine, tenofovir, entecavir), drugs for portal hypertension (propranolol, terlipressin, octreotide, vasopressin), lactulose and rifaximin for hepatic encephalopathy, UDCA for cholestasis, hepatotoxic drugs and DILI mechanisms.

Katzung's Basic and Clinical Pharmacology, 16th Edition

• ISBN: 9781260463309 | 13 blocks
• Antiviral agents for HBV/HCV, hepatic drug metabolism (CYP450), first-pass effect, hepatic clearance pharmacokinetics, drug dosing in liver failure.

Lippincott Illustrated Reviews: Pharmacology

• ISBN: 9781975170561 | 5 blocks
• Concise hepatology pharmacology: antivirals, drugs for complications of liver disease, quick-reference tables.

---

MICROBIOLOGY

Medical Microbiology, 9th Edition (Murray)

• ISBN: 9780323673228 | 9 blocks
• Hepatotropic viruses: HAV (Hepatovirus), HBV (Hepadnavirus - Dane particle, surface antigen, core antigen, e antigen, DNA polymerase, replication cycle), HCV (Flavivirus - genotypes, quasispecies), HDV (delta agent, requires HBsAg), HEV (waterborne, fulminant in pregnancy), EBV and CMV liver involvement, liver flukes (Clonorchis, Fasciola, Opisthorchis), Entamoeba histolytica (amoebic liver abscess), Echinococcus (hydatid cyst), leptospirosis (Weil's disease), brucellosis with hepatic granulomas, Q fever.

Jawetz, Melnick & Adelberg's Medical Microbiology, 28th Edition

• ISBN: 9781260012026 | 7 blocks
• Detailed virology of hepatitis viruses, serological markers (HBsAg, anti-HBs, HBeAg, anti-HBe, anti-HBc IgM/IgG), window period, carrier state, hepatitis C genotyping.

Sherris & Ryan's Medical Microbiology, 8th Edition

• ISBN: 9781260464283 | 7 blocks
• Similar viral hepatitis coverage with clinical correlation and epidemiology.

---

PHYSIOLOGY

Guyton and Hall Textbook of Medical Physiology

• ISBN: 9780443111013 | 10 blocks
• Liver physiology: bile formation and secretion, bilirubin metabolism (unconjugated - conjugated - urobilinogen cycle), liver blood flow and portal circulation, hepatic metabolic functions (glycogen storage, gluconeogenesis, lipid metabolism, protein synthesis - albumin/clotting factors, urea cycle, detoxification), liver function tests, jaundice physiology.

Ganong's Review of Medical Physiology, 26th Edition

• ISBN: 9781260122404 | 6 blocks
• Portal circulation, enterohepatic circulation of bile salts, hepatic first-pass metabolism, liver in metabolism of hormones and drugs.

Costanzo Physiology, 7th Edition

• ISBN: 9780323793339 | 4 blocks
• Concise liver physiology: bilirubin handling, jaundice classification (pre-hepatic, hepatic, post-hepatic).

Medical Physiology (Boron & Boulpaep)

• ISBN: 9780323319737 | 14 blocks
• Most detailed liver physiology: hepatocyte ultrastructure, bile canaliculi, transport proteins (OATP, MRP2, BSEP), bile acid synthesis and recycling, hepatic zonation (zones 1-3), oxygen gradient, metabolic heterogeneity.

---

BIOCHEMISTRY

Harper's Illustrated Biochemistry, 32nd Edition

• ISBN: 9781260469943 | 6 blocks
• The central biochemistry of the liver: bilirubin metabolism (heme catabolism - unconjugated bilirubin - UDP-glucuronyl transferase - conjugated - excretion), urea cycle (ornithine cycle - liver-specific), bile acid synthesis (cholesterol - 7-alpha-hydroxylase - primary bile acids - conjugation with glycine/taurine), fatty acid metabolism and ketogenesis, gluconeogenesis, glycogen metabolism, acute phase proteins, liver-specific proteins (albumin, fibrinogen, prothrombin), carnitine synthesis.

Lippincott Illustrated Reviews: Biochemistry, 8th Edition

• ISBN: 9781975155063 | 4 blocks
• Bilirubin metabolism with clear diagrams, heme degradation pathway, jaundice biochemistry, urea cycle defects with clinical correlations.

Basic Medical Biochemistry: A Clinical Approach, 6th Edition

• ISBN: 9781975150143 | 9 blocks
• Clinical biochemistry of liver disease: LFTs interpretation, AST/ALT/ALP/GGT/bilirubin, coagulation factors and liver disease, albumin as marker of synthetic function.

---

ANATOMY

Gray's Anatomy for Students

• ISBN: 9780323934237 | 6 blocks
• Liver anatomy: lobes (right, left, caudate, quadrate), ligaments (falciform, coronary, triangular, lesser omentum), porta hepatis contents (portal vein, hepatic artery, bile duct), Couinaud segmental anatomy (8 segments), hepatic veins draining to IVC, blood supply (dual - portal vein 75% + hepatic artery 25%), lymphatics, innervation. Also: biliary system - gallbladder, cystic duct, CHD, CBD, sphincter of Oddi.

Color Atlas of Human Anatomy Vol. 2 - Internal Organs

• ISBN: 9783132424487 | 2 blocks
• Full-color atlas images of liver anatomy, gallbladder, biliary tree, hepatic vessels.

Netter's Atlas of Human Anatomy

• ISBN: 9780323547048 | 1 block
• Classic Netter illustrations of liver, portal system, hepatic segments, biliary tract.

---

EMERGENCY MEDICINE (Liver emergencies)

Tintinalli's Emergency Medicine: A Comprehensive Study Guide

• ISBN: 9781260019933 | 7 blocks - Chronic hepatitis and cirrhosis section
• Acute liver failure, management of variceal bleeding, hepatic encephalopathy in ED, spontaneous bacterial peritonitis, hepatorenal syndrome, acute-on-chronic liver failure.

Rosen's Emergency Medicine, Concepts and Clinical Practice

• ISBN: 9780323757898 | 32+ blocks
• Emergency management of liver-related presentations.

---

HOW TO ACCESS CONTENT

• "Explain HBV replication cycle from Jawetz microbiology"
• "Give me cirrhosis complications from Harrison's"
• "Bilirubin metabolism from Harper's biochemistry"
• "Liver anatomy - Couinaud segments from Gray's"
• "Portal hypertension pharmacology from Goodman & Gilman"
• "Liver pathology - HCC from Robbins"

---

---

ANATOMY OF THE LIVER - Full Textbook-Level Notes

---

1. OVERVIEW AND POSITION

• Primarily in the right hypochondrium and epigastric region, extending into the left hypochondrium
• Lies mostly below the right dome of the diaphragm
• The inferior border runs diagonally to the left, passing through the epigastric region, intersecting the midclavicular line
• In vivo it is almost completely covered by the thoracic cage (ribs 7-11 on the right side)

---

2. SURFACES OF THE LIVER

A. Diaphragmatic Surface

• Smooth and domed
• Faces anteriorly, superiorly, and posteriorly against the inferior surface of the diaphragm
• Divided into:
  • Anterior part - the largest part, divided by the falciform ligament into right and left lobes
  • Superior part - faces cephalad; near the IVC the liver is attached to the diaphragm at the bare area
  • Right part - the right lateral portion
  • Posterior part - small, posteriorly directed portion

• Right subphrenic recess - between the right diaphragmatic surface and the diaphragm, to the right of the falciform ligament
• Left subphrenic recess - to the left of the falciform ligament
• Hepatorenal recess (Morrison's pouch) - peritoneal cavity on the right side between the liver and the right kidney/right suprarenal gland; clinically the most dependent recess in the supine patient - free fluid accumulates here first

B. Visceral Surface

• Slightly concave, faces inferiorly and posteriorly
• Covered by visceral peritoneum except at the gallbladder fossa and porta hepatis
• Subdivided by an H-shaped set of grooves:

• Left side: esophageal impression, gastric impression, omental tuberosity
• Right side: duodenal impression, colic impression (right colic flexure), renal impression (right kidney), suprarenal impression

---

3. LOBES OF THE LIVER

Morphological (Anatomical) Lobes - based on external surface landmarks

Important: The traditional 4-lobe division based on external surface features does NOT correspond to the functional (surgical) division of the liver. The functional division is based on the vascular and biliary distribution.

---

4. COUINAUD'S SEGMENTAL ANATOMY (8 Segments)

The Principal Plane (Cantlie's Line)

• An imaginary parasagittal line passing through the gallbladder fossa to the inferior vena cava
• Divides the liver into right half and left half of approximately equal size
• The middle hepatic vein lies in this plane
• This is the surgically relevant division - NOT the anatomical right/left lobe division

Segment Numbering (clockwise from caudate lobe):

• Segment I = Caudate lobe (unique - has direct venous drainage into IVC, independent of hepatic veins)
• Segment II = Left lateral superior area (lateral segment, superior)
• Segment III = Left lateral inferior area (lateral segment, inferior)
• Segment IV = Left medial area (quadrate lobe = IVa superior + IVb inferior)
• Segment V = Right anterior inferior area
• Segment VI = Right posterior inferior area
• Segment VII = Right posterior superior area
• Segment VIII = Right anterior superior area

Surgical Resections Based on Segments:

• Right hepatectomy: Segments V + VI + VII + VIII removed; I + II + III + IV remain
• Left hepatectomy: Segments II + III + IV removed; I + V + VI + VII + VIII remain
• Extended right hepatectomy: V + VI + VII + VIII + IV
• Left lateral sectionectomy: II + III
• Individual segment resections possible due to independent pedicles

---

5. LIGAMENTS OF THE LIVER

The Bare Area

• Located on the posterior diaphragmatic surface of the right lobe
• No peritoneum between liver and diaphragm here
• Bounded anteriorly by anterior coronary ligament, posteriorly by posterior coronary ligament
• Clinically relevant: pathway for spread of subphrenic abscess or retroperitoneal gas

---

6. VISCERAL SURFACE - PORTA HEPATIS

1. Portal vein (posterior)
2. Hepatic artery proper - divides into right and left hepatic arteries
3. Nerves (hepatic plexus, from celiac plexus)

1. Right hepatic duct + Left hepatic duct (join to form the common hepatic duct)
2. Lymphatic vessels

• Bile duct (right/anterolateral)
• Hepatic artery (left/anteromedial)
• Portal vein (posterior)
• "BD, HA, PV" or "The Patient Has Blood" (PV posterior, HA left, BD right)

---

7. BLOOD SUPPLY - DUAL CIRCULATION

Arterial Supply - Origin and Course:

• Right hepatic artery → supplies right lobe (segments V-VIII)
  • Also gives off cystic artery → gallbladder
• Left hepatic artery → supplies left lobe (segments II-IV)

Portal Vein Formation:

• Superior mesenteric vein + Splenic vein join posterior to the neck of the pancreas
• The inferior mesenteric vein joins the splenic vein (or SMV junction)
• Portal vein ascends in the hepatoduodenal ligament (posterior to bile duct and hepatic artery)

Venous Drainage:

• Right, Middle, and Left hepatic veins → drain directly into the inferior vena cava (IVC) just below the diaphragm
• The middle hepatic vein often joins the left hepatic vein before entering the IVC
• Caudate lobe drains directly into the IVC via small separate veins (hence preserved in Budd-Chiari syndrome)
• Hepatic veins have NO valves

Clinical Point - Portal Hypertension and Portosystemic Anastomoses:

---

8. LYMPHATIC DRAINAGE

• Most abundant lymph production in the body - the liver produces ~25-50% of thoracic duct lymph
• Superficial lymphatics from the diaphragmatic surface → follow hepatic veins → hepatic lymph nodes at porta hepatis → celiac lymph nodes → cisterna chyli → thoracic duct
• Deep lymphatics travel with portal tracts → hepatic lymph nodes
• Some lymphatics from the bare area pass directly through the diaphragm → posterior mediastinal lymph nodes

---

9. NERVE SUPPLY

• Sympathetic (T7-T10): Via celiac plexus → hepatic plexus → travels with hepatic artery branches; vasomotor function
• Parasympathetic: Vagus nerve (both left and right vagal trunks) → hepatic branches → porta hepatis
• Phrenic nerve (C3-C5): Supplies the capsule of the liver (Glisson's capsule) and diaphragm → referred pain to right shoulder tip (C4 dermatome) in liver/biliary disease

---

10. MICROSCOPIC ANATOMY (HISTOLOGY)

Model 1 - Classical (Portal) Lobule

• Hexagonal unit
• Central vein at the center (drains into hepatic vein)
• Portal triads (Glisson triads) at the 6 corners, each containing:
  • Interlobular portal vein branch
  • Interlobular hepatic artery branch
  • Bile ductule
  • All enclosed in connective tissue of Glisson's capsule
• Hepatocytes radiate outward in plates (cords) from the central vein
• Sinusoids run between hepatocyte plates from portal triads toward the central vein
• Blood flows: portal triad → sinusoids → central vein
• Bile flows in opposite direction: hepatocytes → bile canaliculi → portal tract bile ductule

Model 2 - Portal Lobule

• Triangle with portal triad at center
• Emphasizes bile flow direction
• Central veins at the 3 corners

Model 3 - Hepatic Acinus (Rappaport's Acinus) - Most Clinically Relevant

• Diamond-shaped unit
• Axis = terminal portal venule (and hepatic arteriole) from the portal tract
• Three concentric zones based on distance from the blood supply:

Key Cellular Components:

Space of Disse

• Perisinusoidal space between sinusoidal endothelium and hepatocyte microvilli
• Contains: stellate cells (Ito cells), plasma (percolates through endothelial fenestrations), reticulin fibers
• Where hepatocyte microvilli project - maximizing exchange surface area
• Hepatocytes have direct contact with blood through this space (no basement membrane barrier)

Bile Canaliculi

• Not separate tubes - formed by grooves between adjacent hepatocytes, sealed by tight junctions
• ~1-2 µm diameter
• Bile flows from zone 3 → zone 1 → bile ductules (canals of Hering) → interlobular bile ducts in portal tracts
• Bile flow is in the opposite direction to blood flow

---

11. BILIARY SYSTEM ANATOMY

Intrahepatic Biliary System

• Bile canaliculi → canals of Hering (hepatocyte to cholangiocyte transition) → interlobular bile ductules → segmental bile ducts → right and left hepatic ducts

Extrahepatic Biliary System

1. Descends in the free edge of hepatoduodenal ligament (to the right of hepatic artery, anterior to portal vein)
2. Passes posterior to the superior part of the duodenum
3. Passes in a groove on the posterior surface of the head of the pancreas
4. Joins the main pancreatic duct (of Wirsung) → forms the hepatopancreatic ampulla (of Vater)
5. Opens into the descending (2nd) part of the duodenum at the major duodenal papilla
6. Surrounded by the sphincter of Oddi (sphincter of the hepatopancreatic ampulla)

Gallbladder

• Pear-shaped sac, capacity ~50 mL
• Lies in the gallbladder fossa between the right and quadrate lobes
• Parts: Fundus (projects below inferior border, level of tip of 9th costal cartilage at the midclavicular line) → Body (against transverse colon and duodenum) → Neck (with spiral valves of Heister - mucosal spiral folds) → Cystic duct
• Function: receives, concentrates (~10-fold), and stores bile
• Arterial supply: Cystic artery from the right hepatic artery (within the hepatocystic triangle - Calot's triangle)

Calot's Triangle (Hepatocystic Triangle)

• Superior: inferior surface of liver
• Left: common hepatic duct
• Right: cystic duct

• Surgically important during cholecystectomy

---

12. RELATIONS OF THE LIVER

Anterior Relations:

• Right and left costal margins
• Xiphoid process and anterior abdominal wall (small strip)
• Diaphragm (above)

Posterior Relations (visceral surface):

• Diaphragm (bare area - no peritoneum)
• Right kidney and right suprarenal gland (renal impression)
• Inferior vena cava (in the IVC groove)
• Esophagus (esophageal impression, left lobe)
• Stomach (gastric impression, left lobe)
• Superior duodenum (duodenal impression)
• Right colic flexure (colic impression)

---

13. DEVELOPMENT (EMBRYOLOGY)

• The liver develops from the hepatic diverticulum (hepatic bud) - an outgrowth from the ventral wall of the foregut (future duodenum) during week 4
• The diverticulum grows into the septum transversum (mesenchyme between the pericardial cavity and yolk sac stalk)
• Pars hepatica → liver parenchyma and intrahepatic bile ducts
• Pars cystica → gallbladder and cystic duct
• The falciform ligament is derived from the ventral mesentery
• The lesser omentum is derived from the ventral mesentery
• Hematopoiesis occurs in the fetal liver from week 6 to week 28 (then transfers to bone marrow)
• Ductus venosus - fetal vascular channel from the left branch of portal vein to the IVC, bypassing the hepatic sinusoids; closes at birth → ligamentum venosum
• Umbilical vein (left) carries oxygenated blood from placenta to fetus → closes at birth → ligamentum teres (round ligament)

---

14. CLINICAL ANATOMY - KEY POINTS

---

---

• Physiology (bile secretion, bilirubin metabolism, portal circulation, hepatic metabolic functions)
• Biochemistry (urea cycle, bilirubin pathway, fatty acid metabolism, acute phase proteins)
• Pathology (hepatitis, cirrhosis, NAFLD, HCC - Robbins)
• Microbiology (hepatitis viruses A-E)
• Pharmacology (antivirals, drugs for complications of liver disease)
• Medicine (clinical management of liver diseases - Harrison's)
• Surgery (hepatic resection, portal hypertension surgery)

---

PHYSIOLOGY OF THE LIVER - Full Textbook-Level Notes

---

1. FUNCTIONAL ANATOMY (Physiological Perspective)

• Hepatocyte plates are usually one cell thick
• Plasma is in intimate contact with hepatocytes via the Space of Disse
• Sinusoidal endothelium is fenestrated - pores up to 1 µm diameter, NO basement membrane
• This allows even large plasma proteins to freely enter the Space of Disse
• Kupffer cells (resident macrophages) are anchored to the sinusoidal endothelium, projecting into the lumen
• Each hepatocyte is opposed to both a sinusoid and a bile canaliculus simultaneously - different functional domains (basolateral = blood-facing; apical = bile-facing)

---

2. HEPATIC CIRCULATION AND BLOOD FLOW

Blood Flow Volumes (Guyton & Hall)

Pressures (Ganong)

• Portal venous pressure: ~10 mmHg (normal range 5-10 mmHg)
• Hepatic venous pressure: ~5 mmHg
• Sinusoidal pressure: lower than portal venous pressure
• Hepatic arteriole pressure: ~90 mmHg at branch level - marked drop across hepatic arterioles maintains sinusoidal low pressure

Hepatic Arterial Buffer Response (Ganong)

• When portal flow decreases → adenosine accumulates in periarteriolar space → dilates terminal arterioles → increases hepatic arterial flow
• When portal flow increases → adenosine washed away faster → arterioles constrict → less arterial flow
• Adenosine is produced at a constant metabolic rate; its local concentration governs arteriolar tone
• This buffer response maintains total hepatic blood flow relatively constant despite variation in either input

Sinusoid Recruitment

• Between meals: many sinusoids are collapsed (not perfused)
• After a meal: portal flow increases → "reserve" sinusoids are recruited
• This prevents portal pressure from rising linearly with flow - a protective mechanism

Sympathetic Nervous Control

• Intrahepatic portal vein radicles receive noradrenergic vasoconstrictor fibers (T3-T11 via splanchnic nerves)
• During systemic sympathetic activation (e.g., shock): portal radicles constrict → portal pressure rises → blood is forced through the liver rapidly, bypassing much of hepatic processing → mobilizes ~300-500 mL of blood from the liver reservoir into systemic circulation
• Hepatic artery innervated by hepatic sympathetic plexus
• The liver acts as a blood reservoir - can mobilize large volumes during stress

Hepatic Lymph

• Very high lymph flow - the liver produces 25-50% of total thoracic duct lymph
• The large endothelial pores allow plasma proteins to pass freely into the Space of Disse
• From there, protein-rich fluid enters lymphatic capillaries in the portal tracts
• When hepatic venous pressure rises (e.g., right heart failure, Budd-Chiari): lymph formation overwhelms drainage → ascites (protein-rich in early liver disease)

---

3. HEPATIC VASCULAR RESERVE FUNCTION

• Normal: contains ~450-500 mL of blood (~10% of total blood volume)
• During heart failure with elevated venous pressure: hepatic blood volume increases greatly - can enlarge the liver significantly (hepatomegaly of cardiac failure)
• In hemorrhage/sympathetic activation: hepatic vasculature constricts, releasing blood into systemic circulation

---

4. KUPFFER CELLS - RETICULOENDOTHELIAL FUNCTION

• Portal blood arriving from the intestine carries large numbers of colon bacteria (especially after meals)
• Kupffer cells destroy virtually 99% of bacteria before portal blood passes through the liver
• This is critical because the portal blood percolates slowly through the sinusoids, exposing all bacteria to the Kupffer cells
• Also phagocytize: old/damaged red blood cells, foreign particles, immune complexes

---

5. LIVER REGENERATION

• After a partial hepatectomy (removal of up to 70% of liver mass), the remaining liver cells proliferate until the liver approaches its original size
• Growth factors involved: HGF (hepatocyte growth factor), EGF (epidermal growth factor), TGF-α
• Regulatory restraint: once the liver reaches its appropriate size, further cell division stops - controlled by TGF-β (inhibitory signal)
• Regeneration is also triggered by toxic injury to hepatocytes
• The liver is the only solid organ that can fully regenerate to its original mass

---

6. METABOLIC FUNCTIONS OF THE LIVER

---

A. CARBOHYDRATE METABOLISM

---

B. FAT (LIPID) METABOLISM

---

C. PROTEIN METABOLISM

Plasma Proteins Synthesized by the Liver

---

D. DETOXIFICATION AND EXCRETION

Phase I Reactions (Guyton / Ganong)

• Oxidation, reduction, hydroxylation
• Mediated by cytochrome P450 enzymes (especially CYP3A4, CYP2D6, CYP2C9)
• Convert lipophilic drugs/toxins to more polar, less active metabolites
• Located predominantly in zone 3 (centrilobular) hepatocytes

Phase II Reactions

• Conjugation (glucuronidation, sulfation, acetylation, glutathione conjugation, methylation)
• Make metabolites water-soluble for biliary or renal excretion
• Example: bilirubin glucuronidation by UGT1A1

Hormonal Inactivation (Guyton)

• Thyroxine (T4 → T3 conversion and T4 degradation)
• Steroid hormones: estrogens, cortisol, aldosterone, testosterone - converted to water-soluble glucuronide/sulfate conjugates
• Insulin and glucagon: degraded by liver (~50% of portal insulin extracted on first pass)
• Aldosterone: metabolism by liver; in cirrhosis, reduced aldosterone metabolism → hyperaldosteronism → sodium/water retention → ascites and edema

First-Pass Effect

• Drugs absorbed from the gut pass through the portal circulation and are extensively metabolized by the liver before reaching systemic circulation
• This is the hepatic first-pass effect - reduces bioavailability of many orally administered drugs
• Example: propranolol, morphine, lidocaine have extensive first-pass metabolism
• In liver disease: first-pass effect is reduced → higher systemic drug levels → adjust doses

---

E. VITAMIN AND MINERAL STORAGE

---

7. BILE SECRETION

Overview (Guyton & Hall)

• The liver secretes 600-1000 mL/day of bile
• Bile serves two major functions:
  1. Fat digestion and absorption (emulsification and micelle formation)
  2. Excretion of waste products (bilirubin, cholesterol, drugs, hormones)

Two Stages of Bile Secretion (Guyton)

• Hepatocytes secrete bile into bile canaliculi
• Contains: bile acids, cholesterol, lecithin (phosphatidylcholine), bilirubin
• The active secretion of bile acids is the primary osmotic driving force - bile acid secretion drives water flow into canaliculi
• Canalicular bile is transiently hypertonic; tight junctions between hepatocytes are relatively permeable → water, glucose, calcium, amino acids, glutathione, and urea passively enter

• As bile flows through ductules and ducts, cholangiocytes modify composition
• They secrete a watery Na⁺ and HCO₃⁻-rich fluid (stimulated by secretin → cAMP → CFTR channels)
• Cholangiocytes also scavenge glucose and amino acids back into circulation (via active transport)
• Gamma-glutamyl transpeptidase (GGT) on the apical membrane of cholangiocytes hydrolyzes glutathione
• Stage 2 can increase total bile volume by up to 100%
• Ductal bile: pH 7.8-8.6; final biliary bicarbonate alkalinity helps neutralize gastric acid in duodenum

Composition of Bile

Regulation of Bile Secretion

Gallbladder Contraction

• CCK released from I cells (duodenum/jejunum) in response to fat and protein
• Acts on CCK-A receptors on gallbladder smooth muscle → contraction
• Simultaneously relaxes the Sphincter of Oddi
• Vagal nerve also mediates gallbladder contraction (cephalic phase)
• Somatostatin inhibits gallbladder contraction

---

8. BILE ACIDS AND SALTS

Synthesis

• Liver synthesizes ~6 g/day of bile salts
• Precursor: cholesterol
• Cholesterol → cholic acid (trihydroxy) and chenodeoxycholic acid (dihydroxy) in approximately equal amounts - these are primary bile acids
• Rate-limiting enzyme: 7-alpha-hydroxylase (CYP7A1)
• Primary bile acids are conjugated with glycine (mainly) or taurine (lesser extent) → glycocholic acid, taurocholic acid, glycochenodeoxycholic acid, taurochenodeoxycholic acid
• The sodium and potassium salts of these conjugated bile acids are the bile salts

Secondary Bile Acids

• In the colon, bacteria deconjugate and dehydroxylate primary bile acids:
  • Cholic acid → deoxycholic acid
  • Chenodeoxycholic acid → lithocholic acid
• These secondary bile acids are partially reabsorbed and re-enter the enterohepatic circulation

Functions of Bile Salts (Guyton)

• Bile salts have detergent properties (amphipathic: hydrophilic + hydrophobic portions)
• Decrease surface tension of fat particles
• Agitation in intestinal tract breaks large fat globules into minute particles (~1 µm diameter)
• Increases total surface area for lipase action by ~1000-fold

• Bile salts + fatty acids + monoglycerides + cholesterol + fat-soluble vitamins → mixed micelles
• Micelles are ~3-10 nm diameter water-soluble cylinders
• Transport lipid digestion products from the gut lumen to the brush border of enterocytes
• Without bile salts: up to 40% of ingested fat is lost in stool (steatorrhea)

Enterohepatic Circulation of Bile Salts (Guyton + Ganong)

Liver synthesizes bile salts
        ↓
Secreted into bile → gallbladder → duodenum
        ↓
Emulsification and micelle formation in small intestine
        ↓
~5% diffuse passively from early small intestine (jejunum)
~90% actively reabsorbed from TERMINAL ILEUM (Na⁺-dependent bile salt transporter = ASBT/SLC10A2)
~5% lost in feces (replaced by new synthesis)
        ↓
Absorbed bile salts enter PORTAL BLOOD
        ↓
Liver extracts virtually 100% on first pass
        ↓
Re-secreted into bile (recycled)

• Total bile salt pool = ~2.5 g
• Recycled 6-10 times per day
• Total bile salt flux per day = ~15-25 g
• If terminal ileum is diseased (Crohn's disease) or resected: bile salt malabsorption → steatorrhea, fat-soluble vitamin deficiency, cholerheic diarrhea
• Cholestyramine (bile acid sequestrant) interrupts this cycle → forces liver to synthesize new bile acids from cholesterol → lowers serum cholesterol

---

9. BILIRUBIN METABOLISM AND EXCRETION

Step 1 - Formation of Bilirubin (in Macrophages)

• 65-80% from breakdown of hemoglobin of senescent red blood cells (RBC lifespan = 120 days)
• Remaining 20-35% from: myoglobin, cytochromes, ineffective erythropoiesis ("early labeled peak")

1. Senescent RBCs → phagocytized by macrophages (spleen, bone marrow, Kupffer cells)
2. Hemoglobin → split into globin + heme
3. Heme ring opened by heme oxygenase (NADPH + O₂ required) → biliverdin (green pigment) + free iron (Fe³⁺) + CO
4. Biliverdin reductase (NADPH required) → bilirubin (yellow pigment)
5. Free iron bound to transferrin for recycling

Step 2 - Transport in Blood

• Bilirubin formed in macrophages is lipophilic and insoluble in water
• Binds strongly but reversibly to albumin in plasma → "albumin-bound unconjugated bilirubin"
• Also called: unconjugated bilirubin = indirect bilirubin (reacts only after addition of alcohol in van den Bergh test)
• Normal plasma concentration: 0.1-0.5 mg/dL (mostly unconjugated)
• Does NOT appear in urine (albumin-bound, cannot be filtered by kidney)
• TOXIC to brain when unbound (in neonates: kernicterus when free unconjugated bilirubin crosses blood-brain barrier)

Step 3 - Hepatic Uptake

• Albumin-bilirubin complex enters Space of Disse via sinusoidal fenestrations
• Bilirubin dissociates from albumin
• Uptake across basolateral (sinusoidal) membrane by:
  • OATP1B1 and OATP1B3 (Organic Anion Transporting Polypeptides) - primary carriers
  • Additional passive/facilitated mechanisms
• Inside hepatocyte: bilirubin bound to ligandin (Y protein / glutathione-S-transferase) → prevents back-diffusion

Step 4 - Conjugation (in Hepatocyte ER)

• UDP-glucuronyl transferase (UGT1A1) in smooth ER
• Bilirubin + UDP-glucuronic acid → bilirubin glucuronide
  • ~80% → bilirubin diglucuronide (predominant conjugated form)
  • ~10% → bilirubin monoglucuronide
  • ~10% → bilirubin sulfate and other conjugates
• Conjugated bilirubin = direct bilirubin (reacts directly in van den Bergh test without alcohol)
• Now water-soluble, non-toxic, can be filtered by kidney

Step 5 - Canalicular Secretion

• Conjugated bilirubin secreted from hepatocyte into bile canaliculus by MRP2 (ABCC2) - ATP-dependent (active transport)
• This is the rate-limiting step in hepatic bilirubin handling
• Defect in MRP2 → Dubin-Johnson syndrome (conjugated hyperbilirubinemia)

Step 6 - Intestinal Metabolism (Enterohepatic Bilirubin Cycle)

• Conjugated bilirubin arrives in terminal ileum and colon
• Intestinal bacteria (beta-glucuronidases) → deconjugate bilirubin → free bilirubin
• Further bacterial reduction → urobilinogen (colorless, highly soluble)
• Fate of urobilinogen:
  • ~80-90% remains in colon → oxidized to stercobilin → excreted in feces (gives stool its brown color)
  • ~10-20% reabsorbed from colon/terminal ileum → enters portal blood → most re-excreted by liver (enterohepatic circulation) → ~5% escapes to systemic circulation → kidney → urine → oxidized to urobilin (yellow color of urine)

Summary Table: Types of Jaundice

Important Inherited Disorders of Bilirubin Metabolism

---

10. CHOLESTEROL AND GALLSTONE FORMATION

Hepatic Cholesterol Secretion (Ganong/Guyton)

• The liver secretes cholesterol into bile in a micellar solution together with bile acids and phosphatidylcholine (lecithin)
• The ratio in canalicular bile: bile acids : phosphatidylcholine : cholesterol ≈ 10 : 3 : 1
• If this ratio is disturbed (↑ cholesterol or ↓ bile acids), cholesterol precipitates → cholesterol gallstones (80% of gallstones in Western populations)

Gallstone Risk

• Deviations from the bile acid:lecithin:cholesterol ratio (above line ABC on Admirand-Small triangle) → cholesterol saturation → nucleation → gallstone formation
• Risk factors: obesity, rapid weight loss, prolonged fasting, ileal disease (reduced bile salt pool), female sex, OCPs, fibrates

---

11. PORTAL HYPERTENSION AND HEPATIC ENCEPHALOPATHY

Portal Hypertension (Boron & Boulpaep / Ganong)

• Normal portal pressure: ~10 mmHg
• Portal hypertension defined as: portal pressure > 12 mmHg (or hepatic venous pressure gradient > 10 mmHg)
• When sinusoidal resistance rises (cirrhosis, fibrosis): portal pressure rises
• Because hepatic sinusoids are highly permeable (low reflection coefficient), even small increases in pressure lead to massive lymph formation and ascites
• In cirrhosis: hardening and fibrosis of liver → resistance to sinusoidal flow → backup of portal pressure → all portosystemic collaterals open up (see anatomy section)

Hepatic Encephalopathy (Ganong)

• In portal hypertension: blood bypasses the liver via collaterals → gut-derived toxins (especially ammonia/NH₃) enter systemic circulation
• Ammonia is the primary toxin: derived from gut bacteria deaminating amino acids; normally detoxified by liver → urea (urea cycle)
• In liver failure: urea cycle fails → NH₃ accumulates → brain toxicity
• Other toxins: mercaptans, short-chain fatty acids, false neurotransmitters (octopamine), GABA-like substances
• Treatment: lactulose (traps NH₃ as NH₄⁺ in gut lumen) + rifaximin (non-absorbed antibiotic reduces gut bacteria) + restrict dietary protein

---

12. HEPATIC REGULATION OF BLOOD GLUCOSE - THE "GLUCOSE BUFFER" FUNCTION

---

13. LIVER FUNCTION TESTS - PHYSIOLOGICAL BASIS

---

14. HEPATIC FIRST-PASS METABOLISM AND PHARMACOKINETICS

• The liver is the primary site of drug metabolism in the body
• Drug oral absorption → portal vein → liver → extensive first-pass hepatic metabolism → systemic circulation
• Bioavailability = fraction of oral dose reaching systemic circulation after first-pass metabolism
• High first-pass drugs: propranolol (bioavailability ~25%), morphine (~25%), aspirin, lidocaine, nitrates, verapamil, statins (some)
• Hepatic blood flow-limited drugs (flow-dependent): Lidocaine, propranolol - extraction so complete that clearance depends on hepatic blood flow, not enzyme activity
• Enzyme-limited (capacity-dependent) drugs: Warfarin, phenytoin - extraction limited by enzyme capacity/affinity
• In liver disease: reduced first-pass → increased bioavailability of many drugs → dose reduction needed
• In portal hypertension: portosystemic shunting → drugs bypass liver entirely → even greater bioavailability

---

---

• Biochemistry (urea cycle in detail, bilirubin pathway at molecular level, fatty acid metabolism, ketone bodies, Harper's + Lippincott)
• Pathology (hepatitis, cirrhosis, NAFLD, HCC - Robbins)
• Microbiology (Hepatitis A-E viruses in depth)
• Pharmacology (antivirals, lactulose, rifaximin, terlipressin, UDCA, statins and liver)
• Medicine (clinical management - Harrison's)
• Surgery (hepatic resection, portal hypertension surgery)

---

BIOCHEMISTRY OF THE LIVER - Full Textbook-Level Notes

---

1. THE LIVER AS THE CENTRAL METABOLIC ORGAN

1. Carbohydrate metabolism (glycolysis, gluconeogenesis, glycogen synthesis/breakdown)
2. Lipid metabolism (beta-oxidation, ketogenesis, fatty acid synthesis, cholesterol/lipoprotein synthesis)
3. Protein/amino acid metabolism (transamination, deamination, urea cycle, plasma protein synthesis)
4. Bilirubin metabolism
5. Detoxification (Phase I and Phase II drug metabolism)
6. Bile acid synthesis
7. Vitamin and mineral storage

---

2. CARBOHYDRATE METABOLISM IN THE LIVER

A. Glycolysis and Glucokinase

• Hepatocytes express glucokinase (hexokinase IV) - a high-Km, high-capacity, non-saturable enzyme for glucose
• Unlike hexokinase in other tissues, glucokinase is NOT inhibited by its product glucose-6-phosphate
• This allows the liver to act as a glucose buffer: after a meal, when portal glucose is high, the liver phosphorylates and traps large amounts of glucose
• Glucokinase is induced by insulin and repressed by fasting

B. Glycogen Synthesis (Glycogenesis)

• Glucose-6-phosphate → glucose-1-phosphate (phosphoglucomutase) → UDP-glucose (UDP-glucose pyrophosphorylase) → glycogen (glycogen synthase)
• Glycogen synthase is the key regulatory enzyme: activated by insulin (dephosphorylation) and glucose-6-phosphate; inactivated by glucagon/epinephrine (phosphorylation via PKA)
• Branching enzyme creates alpha-1,6-glycosidic branch points every 8-10 residues
• Liver glycogen = ~100 g (muscle = ~400 g); liver glycogen primarily for maintaining blood glucose; muscle glycogen for local use only

C. Glycogenolysis

• Glycogen phosphorylase (rate-limiting): cleaves alpha-1,4 bonds → glucose-1-phosphate
• Activated by: glucagon (via cAMP → PKA → phosphorylase kinase → glycogen phosphorylase), epinephrine, calcium (in muscle)
• Debranching enzyme handles the alpha-1,6 branch points → releases free glucose
• Glucose-1-phosphate → glucose-6-phosphate → glucose-6-phosphatase (liver only, NOT muscle) → free glucose exported to blood
• Muscle lacks glucose-6-phosphatase → cannot export glucose (muscle glycogen is for local use)

D. Gluconeogenesis

• Synthesis of glucose from non-carbohydrate precursors - occurs almost exclusively in liver and kidney cortex
• Substrates:
  • Lactate (from anaerobic glycolysis in RBCs, muscles) → pyruvate → glucose (Cori cycle)
  • Alanine (from muscle protein catabolism) → pyruvate → glucose (glucose-alanine cycle)
  • Glycerol (from lipolysis of triglycerides in adipose tissue) → glycerol-3-phosphate → DHAP → glucose
  • Glucogenic amino acids (all except leucine and lysine)
  • Propionate (from odd-chain fatty acid oxidation)

• Activated by: glucagon (↑cAMP → ↑PEPCK expression, ↑fructose-2,6-bisphosphatase → ↓F2,6-BP → relieves PFK-1 activation → allows F1,6-BPase to act), cortisol (induces PEPCK), fasting/starvation, high ATP:ADP ratio
• Inhibited by: insulin (↓PEPCK transcription), high AMP (inhibits PEPCK), high F2,6-bisphosphate

---

3. LIPID METABOLISM IN THE LIVER

A. Fatty Acid Catabolism - Beta-Oxidation

1. Fatty acid + CoA + ATP → Fatty acyl-CoA (catalyzed by fatty acyl-CoA synthetase/thiokinase; outer mitochondrial membrane)
2. Fatty acyl-CoA + carnitine → acylcarnitine + CoA (catalyzed by CPT-I = carnitine palmitoyltransferase I; outer mitochondrial membrane)
   • CPT-I is the rate-limiting step and the key regulatory site of beta-oxidation
   • CPT-I is inhibited by malonyl-CoA (the first intermediate of fatty acid synthesis) - this prevents simultaneous synthesis and oxidation of fatty acids
3. Acylcarnitine transported across inner mitochondrial membrane by carnitine-acylcarnitine translocase (antiporter, exchanges for free carnitine)
4. Acylcarnitine + CoA → acyl-CoA + carnitine (catalyzed by CPT-II; inner membrane)
5. Acyl-CoA enters beta-oxidation spiral in mitochondrial matrix

• 7 cycles × (1 FADH₂ + 1 NADH) = 7 FADH₂ + 7 NADH
• 8 acetyl-CoA → 8 × 10 ATP = 80 ATP
• Total = 7(1.5) + 7(2.5) + 80 - 2 (for activation) = 106 ATP net

B. Ketone Body Synthesis (Ketogenesis) - Occurs Exclusively in Liver Mitochondria

2 Acetyl-CoA → Acetoacetyl-CoA  [thiolase]
Acetoacetyl-CoA + Acetyl-CoA → HMG-CoA  [HMG-CoA synthase] ← rate-limiting step
HMG-CoA → Acetoacetate + Acetyl-CoA  [HMG-CoA lyase]
Acetoacetate → β-Hydroxybutyrate  [β-hydroxybutyrate dehydrogenase; NADH-dependent]
Acetoacetate → Acetone (spontaneous, non-enzymatic decarboxylation; minor)

• The liver produces ketone bodies but cannot use them (lacks succinyl-CoA:acetoacetate CoA transferase = thiophorase)
• Ketone bodies are exported via blood to brain, heart, skeletal muscle, kidney for use as fuel
• In prolonged starvation, brain adapts to use ketone bodies as primary fuel (up to 70%), sparing glucose/protein
• β-Hydroxybutyrate is the predominant ketone body in starvation
• Acetone is volatile → excreted in breath (fruity smell in diabetic ketoacidosis)
• Clinical: Diabetic Ketoacidosis (DKA): Severe insulin deficiency → uncontrolled lipolysis → massive beta-oxidation → massive ketogenesis → ketoacidosis

• Malonyl-CoA levels control CPT-I: high malonyl-CoA (active lipogenesis, fed state) → ↓CPT-I → ↓beta-oxidation → ↓ketogenesis
• In fasting/DM: insulin ↓ → malonyl-CoA ↓ (ACC inhibited by glucagon) → CPT-I active → ↑beta-oxidation → ↑ketogenesis

C. Fatty Acid Synthesis (De Novo Lipogenesis)

• Acetyl-CoA + OAA → citrate (in mitochondria) → exported to cytosol → cleaved by ATP-citrate lyase → acetyl-CoA + OAA in cytosol

1. Acetyl-CoA + CO₂ + ATP → Malonyl-CoA catalyzed by acetyl-CoA carboxylase (ACC) - the committed, rate-limiting step
   • Requires biotin cofactor
   • Activated by: citrate (allosteric), insulin (dephosphorylation)
   • Inhibited by: palmitoyl-CoA (product inhibition), glucagon/epinephrine (phosphorylation via AMP kinase), malonyl-CoA itself at high concentrations
2. Fatty acid synthase complex (FAS) - a multifunctional enzyme in eukaryotes with 7 enzymatic activities:
   • Catalyzes sequential addition of 2-carbon malonyl units onto acetyl-CoA starter unit
   • Each elongation cycle: reduction (NADPH) → dehydration → reduction (NADPH)
   • Product: Palmitate (C16:0) - the primary product of FAS in humans
   • Overall reaction: Acetyl-CoA + 7 Malonyl-CoA + 14 NADPH + H⁺ → Palmitate + 7CO₂ + 14 NADP⁺ + 8 CoA + 6H₂O

• Pentose phosphate pathway (main source, also liver)
• Malic enzyme (malate → pyruvate + CO₂ + NADPH)

D. Cholesterol Synthesis

• 3 Acetyl-CoA → HMG-CoA (via thiolase and HMG-CoA synthase)

• Enzyme: HMG-CoA reductase (ER membrane)
• Reaction: HMG-CoA + 2 NADPH → Mevalonate + CoA
• This is the target of statins (competitive inhibitors of HMG-CoA reductase)

• Requires 3 ATP; produces CO₂

• 2 × IPP → GPP (geranyl-PP, C10) → FPP (farnesyl-PP, C15) → squalene (C30, by squalene synthase, requires NADPH)

• Squalene → lanosterol (by squalene epoxidase + cyclase) → cholesterol (multiple steps, ~20 reactions)

• HMG-CoA reductase - master regulatory enzyme:
  • Transcriptional: regulated by SREBP (sterol response element binding protein) system:
    • When intracellular cholesterol ↓: SCAP (SREBP cleavage-activating protein) escorts SREBP to Golgi → cleaved by proteases → activated SREBP enters nucleus → activates HMG-CoA reductase gene transcription
    • When cholesterol ↑: INSIG proteins retain SCAP-SREBP in ER → no gene transcription
  • Post-translational: cholesterol promotes ubiquitination and proteasomal degradation of HMG-CoA reductase
  • Phosphorylation: AMP kinase phosphorylates and inactivates HMG-CoA reductase (like ACC); insulin activates phosphatase → activates HMG-CoA reductase
  • Induced by: insulin, thyroid hormone
  • Inhibited by: statins, glucagon, glucocorticoids, bile acids (via FXR)

• Bile acids (main route of cholesterol excretion)
• Steroid hormones (in adrenal, gonads - not liver)
• Vitamin D3 precursor

E. Bile Acid Synthesis (Harper's + Ganong)

• Cholesterol → 7α-hydroxycholesterol (enzyme: CYP7A1 = 7-alpha-hydroxylase - rate-limiting step)
• Two pathways diverge → cholic acid (trihydroxy, 3α,7α,12α-OH) and chenodeoxycholic acid (dihydroxy, 3α,7α-OH)
• These are conjugated with glycine (mainly) or taurine → glycocholic acid, taurocholic acid, glycochenodeoxycholic acid, taurochenodeoxycholic acid = primary bile salts secreted into bile

• Cholic acid → deoxycholic acid (by 7-dehydroxylation)
• Chenodeoxycholic acid → lithocholic acid (by 7-dehydroxylation)

• Feedback regulation via FXR (Farnesoid X Receptor = nuclear bile acid-binding receptor):
  • When bile acid pool is large (abundant bile acids in enterohepatic circulation) → bile acids bind FXR → FXR activated → suppresses CYP7A1 transcription → ↓bile acid synthesis
  • When bile acid pool is depleted → FXR not activated → ↑CYP7A1 transcription → ↑bile acid synthesis
• Chenodeoxycholic acid is most potent FXR activator
• CYP7A1 also upregulated by: cholesterol (substrate availability), insulin (fed state)
• CYP7A1 downregulated by: glucagon, glucocorticoids, thyroid hormone (species-dependent)

F. Lipoprotein Synthesis and Metabolism

• TG + Phospholipid + Cholesterol + ApoB-100 → VLDL (assembled in ER, processed in Golgi)
• MTP (microsomal triglyceride transfer protein) is essential for VLDL assembly - transfers lipids onto ApoB-100
• VLDL secreted into sinusoidal blood → processed in circulation by lipoprotein lipase (LPL) on capillary walls (activated by ApoC-II) → TG hydrolyzed → fatty acids released to tissues → VLDL → IDL → LDL

• LDL binds LDL receptor (recognizes ApoB-100) → receptor-mediated endocytosis → lysosomal degradation → cholesterol released inside cell → suppresses SREBP → ↓HMG-CoA reductase + ↓LDL receptor synthesis + ↑ACAT (stores excess cholesterol as cholesteryl ester)
• Statins → ↓HMG-CoA reductase → ↓intracellular cholesterol → ↑SREBP activation → ↑LDL receptor expression → ↓plasma LDL

• HDL (ApoA-I) accepts free cholesterol from peripheral cells via ABCA1 transporter
• LCAT (lecithin-cholesterol acyltransferase) activated by ApoA-I: esterifies cholesterol → cholesteryl ester stored in HDL core
• HDL-cholesterol transported to liver via SR-BI receptor (selective uptake, not endocytosis) or transferred to LDL/VLDL by CETP (cholesteryl ester transfer protein)
• In liver: cholesterol excreted as bile acids or free cholesterol in bile

---

4. PROTEIN AND AMINO ACID METABOLISM IN THE LIVER

A. Transamination (Aminotransferases)

• Transfer of an α-amino group from an amino acid to an α-keto acid
• Reaction: Amino acid₁ + α-keto acid₂ ⇌ α-keto acid₁ + Amino acid₂
• Freely reversible (equilibrium constant ≈ 1)
• All aminotransferases require pyridoxal phosphate (PLP, Vitamin B₆) as cofactor (covalently bound Schiff base)
• Pyridoxal phosphate acts as an "amino carrier" - accepts the amino group → pyridoxamine phosphate → transfers to α-ketoglutarate

• ALT (Alanine aminotransferase = SGPT): Alanine + α-ketoglutarate ⇌ Pyruvate + Glutamate
  • Found predominantly in liver cytosol → MOST SPECIFIC for liver injury
• AST (Aspartate aminotransferase = SGOT): Aspartate + α-ketoglutarate ⇌ OAA + Glutamate
  • Found in liver, heart, muscle, RBCs → less specific

B. Oxidative Deamination - Glutamate Dehydrogenase

• Enzyme: Glutamate dehydrogenase (GDH) - located in mitochondrial matrix
• Releases free NH₄⁺ (ammonia) - the toxic product that must be detoxified
• Allosteric regulation: Activated by ADP and leucine; Inhibited by ATP and GTP (energy charge regulates NH₃ production)
• GDH links amino acid catabolism to the TCA cycle (α-ketoglutarate enters TCA)

C. Ammonia Transport to the Liver

• Muscle: Pyruvate + Glutamate → Alanine (via ALT); Alanine exported in blood
• Liver: Alanine + α-KG → Pyruvate + Glutamate (via ALT); pyruvate → gluconeogenesis; glutamate → NH₄⁺ (via GDH) → urea cycle

• Glutamate + NH₄⁺ → Glutamine (enzyme: glutamine synthetase; uses ATP; occurs in brain, muscle, lung)
• Glutamine travels in blood to liver/kidney
• In liver: glutaminase → glutamate + NH₄⁺ → urea cycle
• In kidney: glutaminase → NH₄⁺ excreted in urine (important in acidosis)

---

5. THE UREA CYCLE (KREBS-HENSELEIT CYCLE)

Sources of Nitrogen in Urea:

• One nitrogen from NH₄⁺ (from oxidative deamination of glutamate via GDH - mitochondrial)
• One nitrogen from aspartate (in the cytosol - donated via transamination of OAA)
• Carbon + oxygen of urea come from CO₂ (as HCO₃⁻)
• Net reaction: NH₄⁺ + HCO₃⁻ + aspartate + 3ATP → urea + fumarate + 2ADP + AMP + 4Pi

The 5 Steps:

• NH₄⁺ + HCO₃⁻ + 2 ATP → Carbamoyl phosphate + 2 ADP + Pi
• Enzyme: Carbamoyl Phosphate Synthetase I (CPS-I)
  • Location: mitochondrial matrix (of liver and intestine)
  • Requires obligatory allosteric activator: N-acetylglutamate (NAG)
  • Inhibited by excess NH₃ accumulation when NAG is deficient
  • CPS-II (pyrimidine synthesis, cytosol, uses glutamine, NOT NAG) is a different enzyme

• Carbamoyl phosphate + Ornithine → Citrulline + Pi
• Enzyme: Ornithine Transcarbamoylase (OTC)
  • X-linked; most common urea cycle defect
  • Citrulline transported OUT of mitochondria (antiporter - exchanges with ornithine entering)

• Citrulline + Aspartate + ATP → Argininosuccinate + AMP + PPi
• Enzyme: Argininosuccinate Synthetase (ASS)
• This step incorporates the second nitrogen (from aspartate) into the cycle

• Argininosuccinate → Arginine + Fumarate
• Enzyme: Argininosuccinate Lyase (ASL)
• Fumarate → malate → OAA (by cytoplasmic reactions similar to TCA) → transaminated back to aspartate → re-enters cycle (this connects the urea cycle to the TCA cycle = the "argininosuccinate bridge")

• Arginine + H₂O → Urea + Ornithine
• Enzyme: Arginase I (liver cytosol); abundant in liver
• Ornithine re-enters mitochondria to restart the cycle
• Urea excreted by kidneys

Energy Cost:

• 4 high-energy phosphate bonds consumed per urea molecule: 2 ATP → 2 ADP (step 1) + 1 ATP → AMP + PPi (step 3; = 2 equivalents)
• Total = 4 "ATP equivalents" per urea synthesized

Regulation of Urea Cycle:

1. Substrate availability (primary): More NH₄⁺ → more urea (feed-forward regulation). High-protein diet or starvation → urea cycle enzyme synthesis induced.
2. N-Acetylglutamate (NAG): obligatory allosteric activator of CPS-I
   • NAG synthesized by N-acetylglutamate synthase (NAGS): Acetyl-CoA + Glutamate → NAG
   • Arginine activates NAGS → more NAG → activates CPS-I → more urea → more ornithine (via arginase) → cycle accelerates (positive feedback loop)
3. Enzyme induction: High-protein diet and prolonged fasting induce all urea cycle enzyme mRNA levels (severalfold, Harper's)

Urea Cycle Disorders (Inborn Errors):

---

6. BILIRUBIN METABOLISM - IN-DEPTH BIOCHEMISTRY

Step 1: Heme Catabolism → Bilirubin (in Macrophages/RES)

• 65-80%: Hemoglobin breakdown (senescent RBCs, ~200 billion RBCs/day)
• 20-35%: "Early labeled peak" = ineffective erythropoiesis + myoglobin + cytochromes + peroxidases

• CO produced in this reaction is endogenous CO - physiological signaling molecule; also used as biomarker of hemolysis
• Heme oxygenase is substrate-inducible (induced by its own substrate, heme)
• Inducers of heme oxygenase: hemolysis, heavy metals (Co, Cd), hypoxia

• Reduces the central methylene bridge of biliverdin
• Birds and amphibians excrete biliverdin directly; humans reduce it to bilirubin

• Highly lipophilic, sparingly soluble in water
• Can penetrate lipid bilayers and blood-brain barrier
• Toxic to neurons (kernicterus when unbound)
• Has internal hydrogen bonds that make it even more hydrophobic

Step 2: Transport to Liver (Albumin-Bound)

• Bilirubin + Albumin → Bilirubin-albumin complex ("indirect bilirubin")
• Albumin has a high-affinity site (binds ~25 mg bilirubin/100 mL plasma) and a low-affinity site
• Low-affinity bound bilirubin readily dissociates → tissue distribution
• Drug displacement from albumin (salicylates, sulfonamides, certain antibiotics) → releases bilirubin → risk of kernicterus in neonates

Step 3: Hepatic Uptake

• Albumin-bilirubin arrives at sinusoidal membrane (Space of Disse)
• Bilirubin dissociates from albumin
• Uptake transporters (basolateral/sinusoidal membrane):
  • OATP1B1 (SLCO1B1) and OATP1B3 - sodium-independent organic anion transporters
  • Some passive/facilitated diffusion also occurs
• Inside hepatocyte: bilirubin bound to Ligandin (Y protein = glutathione-S-transferase) and Z protein
  • Ligandin prevents back-diffusion and intracellular sequestration in wrong compartments
  • Ligandin is inducible by phenobarbital

Step 4: Conjugation with Glucuronic Acid (UDP-Glucuronosyl Transferase)

• Location: Smooth endoplasmic reticulum (microsomal fraction)
• Enzyme: UDP-glucuronosyltransferase 1A1 (UGT1A1)
• Reaction: Bilirubin + UDP-glucuronic acid → Bilirubin monoglucuronide (BG)
• Further: BG + UDP-glucuronic acid → Bilirubin diglucuronide (BG₂) [the predominant form in bile]
• A small amount is conjugated with sulfate (bilirubin sulfate) or other substances
• Conjugated bilirubin = direct bilirubin = water-soluble + non-toxic + filterable by kidney
• Phenobarbital induces UGT1A1 → used therapeutically in Crigler-Najjar type II and Gilbert's syndrome

Step 5: Canalicular Secretion

• Conjugated bilirubin secreted across apical (canalicular) membrane into bile
• Transporter: MRP2 (ABCC2 = Multidrug Resistance-associated Protein 2) - ATP-dependent active transporter
• This step is rate-limiting for overall hepatic bilirubin processing
• Defect in MRP2 → Dubin-Johnson syndrome

Step 6: Intestinal Transformation

• Bilirubin diglucuronide → terminal ileum/colon → bacterial beta-glucuronidases → deconjugated → free bilirubin → further bacterial reduction → urobilinogen (colorless) → urobilin (yellow, oxidized in urine) or stercobilin (brown, in feces)

Van den Bergh Reaction (Clinical Lab Test):

• Total bilirubin: 0.2 - 1.0 mg/dL
• Direct (conjugated): 0.0 - 0.3 mg/dL
• Indirect (unconjugated): 0.2 - 0.8 mg/dL

Genetic Disorders of Bilirubin Metabolism (Harper's)

---

7. HEPATIC DRUG METABOLISM AND DETOXIFICATION

Phase I Reactions (Functionalization)

• Oxidation, reduction, hydrolysis - introduce or expose a functional group (–OH, –NH₂, –COOH, –SH)
• Primarily by Cytochrome P450 (CYP) enzymes - collectively called "Mixed Function Oxidases (MFO)" or "Microsomal Ethanol Oxidizing System (MEOS)"
• Location: Smooth endoplasmic reticulum (microsomal fraction)
• Mechanism: CYP + NADPH + O₂ → metabolite + NADP⁺ + H₂O; generates a reactive free radical intermediate

1. All are found in smooth ER (microsomal fraction)
2. All bound to phospholipid (phosphatidylcholine) in membrane
3. All are inducible by their own substrates (and less so by other substrates)
4. All generate a reactive free-radical intermediate

• Acetaminophen → glucuronide conjugate (by UGT, ~55%) + sulfate conjugate (by SULT, ~30%) → safe renal excretion
• Small amount (~5-10%) → CYP2E1 → NAPQI (N-acetyl-p-benzoquinoneimine) → conjugated with glutathione → safe mercapturic acid → excreted

• Glucuronide and sulfate pathways saturated
• NAPQI production overwhelms glutathione stores
• Free NAPQI → covalently binds liver cell proteins → centrilobular (zone 3) necrosis
• Treatment: N-acetylcysteine (NAC) replenishes glutathione stores

• Aflatoxin B1 (from Aspergillus flavus on peanuts/stored grains) → CYP2A1 → Aflatoxin B1-8,9-epoxide
• Epoxide forms covalent adducts with guanine in DNA → G→T transversion in p53 tumor suppressor gene (codon 249) → hepatocellular carcinoma (HCC)
• Major cause of HCC in sub-Saharan Africa and Southeast Asia

Phase II Reactions (Conjugation/Biotransformation)

---

8. PLASMA PROTEIN SYNTHESIS BY THE LIVER

Albumin (Most Important - Basic Medical Biochemistry)

• MW = 69 kDa (smallest major plasma protein)
• Normal serum concentration: 3.5-5.0 g/dL
• Constitutes ~60% of total plasma protein but contributes 70-80% of plasma oncotic pressure (due to small size and high concentration - Starling forces)
• Synthesized exclusively by hepatocytes (~12 g/day in adults)
• Half-life: 20 days → falls slowly in chronic liver disease (not acute)
• Functions as carrier protein for:
  • Free fatty acids (FFAs)
  • Bilirubin (unconjugated)
  • Calcium (40% of plasma Ca is albumin-bound)
  • Zinc, copper
  • Steroid hormones (cortisol, estrogen, testosterone)
  • Thyroid hormone (T4)
  • Many drugs (warfarin, NSAIDs, digoxin, benzodiazepines)
• Negative acute phase protein - albumin synthesis decreases during inflammation (shift to acute phase protein production)

Binding Proteins Synthesized by Liver (Basic Med Biochemistry Table)

Acute Phase Proteins (APPs)

• C-Reactive Protein (CRP) - 1000-fold increase; activates complement; opsonin
• Serum amyloid A (SAA)
• Fibrinogen (↑ clotting risk)
• Alpha-1-antitrypsin
• Haptoglobin
• Ceruloplasmin
• Complement C3, C4
• Ferritin

• Albumin (major - explains low albumin in chronic inflammation and sepsis)
• Transferrin
• Transthyretin (prealbumin)
• RBP (retinol-binding protein)

Clotting Factors Synthesized by Liver

• PT/INR rises early (Factor VII has shortest half-life ~4-6 hours) → best test of acute hepatic synthetic function
• In chronic liver disease: all factors fall → PT/INR ↑ + PTT ↑
• Factor V is synthesized by liver but is NOT Vitamin K-dependent → Factor V level can distinguish hepatocellular failure from Vitamin K deficiency/warfarin effect

---

9. HEPATIC METABOLISM OF ETHANOL

Three Pathways:

• Ethanol + NAD⁺ → Acetaldehyde + NADH (ADH; cytosol)
• Acetaldehyde + NAD⁺ → Acetate + NADH (ALDH2 = aldehyde dehydrogenase 2; mitochondria)
• Acetate → blood → peripheral tissues → acetyl-CoA

• Ethanol + NADPH + H⁺ + O₂ → Acetaldehyde + NADP⁺ + 2H₂O
• CYP2E1 is inducible (explains tolerance in alcoholics and increased NAPQI generation)
• Generates reactive oxygen species (ROS) → oxidative stress → lipid peroxidation

• Ethanol + H₂O₂ → Acetaldehyde + 2H₂O (requires H₂O₂ generated by other reactions)

Metabolic Consequences of Excess NADH Production:

• Highly reactive; forms covalent adducts with proteins → impairs protein function
• Binds tubulin → impairs hepatocyte secretion (fat + protein accumulate in cells)
• Binds mitochondrial proteins → mitochondrial dysfunction
• Stimulates stellate cell activation → collagen synthesis → fibrosis

---

10. LIVER FUNCTION TESTS - BIOCHEMICAL BASIS (Basic Medical Biochemistry)

Enzymes (Reflect Hepatocyte Injury):

Synthetic Function Tests:

Bilirubin Tests:

Hepatic Injury Patterns (Basic Medical Biochemistry):

---

11. ONE-CARBON METABOLISM AND THE LIVER

S-Adenosylmethionine (SAM) - Universal Methyl Donor

• Methionine + ATP → SAM (by methionine adenosyltransferase; abundant in liver)
• SAM donates methyl groups to: DNA (methylation of cytosine), RNA, proteins, phospholipids (PC synthesis from PE), norepinephrine → epinephrine, guanidinoacetate → creatine, arsenic detoxification
• After donating methyl group: SAM → S-adenosylhomocysteine (SAH) → homocysteine
• Homocysteine remethylation: Homocysteine + 5-methylTHF → methionine + THF (requires Vitamin B₁₂ as cofactor for methionine synthase)
• Homocysteine transsulfuration: Homocysteine + serine → cystathionine → cysteine (requires Vitamin B₆ as cofactor)
• In liver disease: impaired SAM synthesis → impaired methylation → affects phospholipid synthesis, DNA methylation

Clinical: Homocysteinemia

• Elevated homocysteine → endothelial damage → atherosclerosis risk
• Caused by: Vitamin B₁₂, B₆, or folate deficiency; cystathionine beta-synthase deficiency (homocystinuria)
• Liver disease impairs folate/B₁₂ metabolism → contributes to elevated homocysteine

---

12. GLYCOGEN STORAGE DISEASES - HEPATIC FORMS

---

---

• Pathology (Robbins - hepatitis, cirrhosis, NAFLD, HCC histopathology)
• Microbiology (Hepatitis A-E viruses)
• Pharmacology (drugs for liver disease)
• Medicine (clinical management - Harrison's)
• Surgery (hepatic resection, portal hypertension surgery)

---

PATHOLOGY OF THE LIVER - Full Textbook-Level Notes (Robbins)

---

1. NORMAL LIVER HISTOLOGY - PATHOLOGICAL BASELINE

• Terminal hepatic vein (central hepatic vein) = center
• Portal tracts at periphery
• Periportal = near portal tract; Centrilobular (perivenular) = near central vein
• Blood flows: portal tract sinusoids → central vein

• Zone 1 (periportal) = closest to blood supply → best oxygenated → zone of gluconeogenesis, beta-oxidation, bile acid synthesis
• Zone 2 = intermediate
• Zone 3 (centrilobular/perivenular) = farthest from blood supply → lowest O₂ → zone of glycolysis, lipid synthesis, drug metabolism (CYP450) → most susceptible to ischemic/toxic injury, alcohol, acetaminophen

• Hepatocytes - polyhedral cells with round nuclei, prominent nucleoli; arranged in 1-2 cell thick plates
• Kupffer cells - liver macrophages on luminal face of sinusoids
• Stellate cells (Ito/lipocyte cells) - in Space of Disse; store Vitamin A; when activated → myofibroblasts → fibrosis
• Sinusoidal endothelium - fenestrated (no basement membrane); overlies Space of Disse

---

2. HEPATIC FAILURE

Acute Liver Failure (Basic Pathology)

• Defined as acute liver illness producing hepatic encephalopathy within 6 months of initial diagnosis
• USA causes: Acetaminophen (paracetamol) overdose ~50% of ALF; autoimmune hepatitis, other drugs/toxins, acute hepatitis A and B
• Asia: acute hepatitis B and E predominate

• Gross: Small, shrunken liver (may weigh as little as 700 g); bile-stained; soft, congested
• Micro: Large zones of destruction (zonal necrosis - zone 3 in acetaminophen, zone 1 in phosphorus); occasional islands of regenerating hepatocytes; minimal scarring (acute process, no time to fibrosis)

• Jaundice, nausea, vomiting, fatigue
• Hepatic encephalopathy (most ominous sign) - due to ↑NH₃ (urea cycle fails) + GABA accumulation + false neurotransmitters + short-chain fatty acids → cerebral edema
• Coagulopathy (↑PT/INR - clotting factors fall rapidly)
• Portal hypertension → ascites
• Serum transaminases initially very high → then fall sharply as hepatocytes disappear (not a good sign - "burnout")
• Eventual multiorgan failure → death without liver transplantation

• Hepatorenal syndrome (HRS): Functional renal failure without intrinsic renal disease; caused by splanchnic vasodilation → ↑renin-angiotensin → severe renal vasoconstriction → ↓GFR; reversible with liver transplant
• Coagulopathy: Combined - ↓clotting factors (liver synthesis fails) + ↑consumption (DIC tendency)
• Hepatic encephalopathy: Asterixis (flapping tremor), confusion, coma

---

3. CIRRHOSIS

Definition and General Features (Robbins & Cotran)

1. Parenchymal nodules (usually regenerative)
2. Dense fibrous bands surrounding nodules - portal-to-portal bridging, or portal-to-central bridging
3. Altered vascular architecture - portosystemic shunting, loss of sinusoidal organization
4. Variable degree of ongoing injury, repair, regeneration

• Chronic Hepatitis B
• Chronic Hepatitis C
• MASLD (Metabolic dysfunction-Associated Steatotic Liver Disease = NAFLD)
• Alcoholic-associated liver disease
• Cryptogenic (no identified cause)

• Bumpy surface (depressed scarring alternating with bulging regenerative nodules)
• Normal smooth capsule replaced by irregular surface
• Liver initially enlarged (fatty/viral) → then shrunken (end-stage)

• Fibrous bands: highlighted by special stains (Masson's trichrome = blue collagen; Sirius Red = red collagen)
• Nodule classification:
  • Micronodular (<3 mm): uniform small nodules - seen in alcoholic cirrhosis, hemochromatosis, biliary cirrhosis
  • Macronodular (>3 mm, variable size): seen in chronic viral hepatitis, autoimmune hepatitis (regeneration after subacute necrosis)
  • Mixed: both patterns coexist
• Features of regression: thin, incomplete scars; variable ductular reaction

Pathogenesis of Fibrosis and Cirrhosis

1. Liver injury (alcohol, virus, toxin, metabolic) → hepatocyte death → inflammatory cell recruitment
2. Kupffer cell activation → releases: TGF-β1 (most potent fibrogenic cytokine), TNF-α, IL-1, ROS, platelet-derived growth factor (PDGF)
3. Hepatic stellate cells (Ito cells) in Space of Disse:
   • Normally store vitamin A (quiescent phenotype)
   • Activated by: TGF-β1, PDGF, ROS, acetaldehyde (in alcohol)
   • Become myofibroblasts → proliferate, lose vitamin A, migrate, contract sinusoids
   • Secrete type I and III collagen (fibrosis) and MMP inhibitors (TIMP-1, TIMP-2) → prevents collagen breakdown
4. Fibrous bands form → distort lobular architecture → portosystemic shunts → portal hypertension
5. Cirrhosis is potentially reversible in early stages if injury removed (HCV cure, alcohol cessation) → HSCs undergo apoptosis, MMPs degrade collagen → regression of fibrosis is documented

---

4. PORTAL HYPERTENSION

Causes (Robbins & Cotran Table 18.2)

Pathophysiology (Robbins & Cotran)

1. ↑ Resistance to portal flow at sinusoidal level:
   • Myofibroblast/vascular smooth muscle contraction
   • Scarring and nodule formation
   • ↓ NO production by sinusoidal endothelium + ↑ endothelin-1 + ↑ angiotensinogen → intrahepatic vasoconstriction
   • Sinusoidal arterio-portal shunts (arterial pressure transmitted to portal system)
2. ↑ Portal venous blood flow via hyperdynamic splanchnic circulation:
   • Splanchnic arterial vasodilation (mediated primarily by NO, also prostacyclin, TNF-α) → ↑ splanchnic blood flow → ↑ portal venous inflow

Four Major Consequences of Portal Hypertension:

• Accumulation of fluid in the peritoneal cavity
• Mechanism: portal hypertension → hydrostatic pressure ↑ + hypoalbuminemia → ↑ sinusoidal ultrafiltration; splanchnic vasodilation → ↓ effective circulating volume → ↑ RAA system activation → Na⁺ and water retention
• High protein ascites (exudate-like): in early liver disease (sinusoids very leaky)
• Low protein ascites (transudate-like): in later disease with hypoalbuminemia
• SAAG (serum-ascites albumin gradient) > 1.1 g/dL indicates portal hypertension

• As portal pressure rises → portal blood diverted through collateral channels to systemic veins
• Esophageal varices: Left gastric (coronary) vein → esophageal veins → azygos → most dangerous - rupture → massive hematemesis (mortality 20-30% per episode)
• Caput medusae: Paraumbilical veins → superficial abdominal wall veins → radiating from umbilicus
• Anorectal varices (hemorrhoids): Superior rectal (portal) → middle/inferior rectal (systemic)
• Retroperitoneal shunts (Retzius veins): Usually asymptomatic

• Portal hypertension → splenic venous congestion → splenomegaly
• Hypersplenism → ↑ destruction of blood cells → thrombocytopenia (most common, first) + anemia + leukopenia
• Platelet count typically 50,000-100,000/µL in moderate hypersplenism

• As discussed - functional renal failure; renin-angiotensin activation worsens renal perfusion; principally in cirrhosis, severe alcoholic hepatitis, fulminant failure

---

5. VIRAL HEPATITIS

Clinicopathologic Syndromes (Common to All Hepatotropic Viruses)

A. Acute Hepatitis - Morphology

• Gross: Enlarged, soft, red-brown congested liver
• Micro:
  • Hepatocyte injury patterns: Ballooning degeneration (swollen, clear cytoplasm - earliest sign), eosinophilic degeneration
  • Apoptosis: Acidophil bodies (Councilman bodies) = eosinophilic, rounded, shrunken hepatocytes with pyknotic nuclei - marker of hepatocyte apoptosis
  • Lobular disarray: Loss of normal plate architecture
  • Inflammation: Mixed portal and intralobular infiltrate of lymphocytes, macrophages; neutrophils in alcoholic hepatitis
  • Cholestasis: Bile pigment in hepatocytes and canaliculi
  • Kupffer cell hyperplasia: Enlarged, pigment-laden Kupffer cells
  • Fatty change (steatosis): Particularly in HCV
• Severe acute hepatitis: Bridging necrosis = confluent necrosis connecting portal tracts to central veins (or portal-to-portal or central-to-central) - indicates bad prognosis

B. Chronic Hepatitis - Morphology (>6 months)

• Portal inflammation: Lymphocytic infiltrate in portal tracts (± germinal centers in HCV)
• Interface hepatitis (Piecemeal necrosis) = lymphocyte-mediated destruction of hepatocytes at the limiting plate (junction of portal tract and parenchyma) = cardinal feature of chronic hepatitis
• Lobular activity: Scattered hepatocyte necrosis and inflammation throughout lobule
• Fibrosis: Portal → periportal → bridging → cirrhosis (Metavir scoring F0-F4)
• Mallory-Denk bodies: Eosinophilic hyaline inclusions of cytokeratin intermediate filaments in hepatocytes - seen in alcoholic hepatitis but also in NASH
• Grading (activity = degree of inflammation) and Staging (fibrosis progression)

---

Hepatitis A Virus (HAV)

---

Hepatitis B Virus (HBV)

• Ground-glass hepatocytes: Finely granular, eosinophilic cytoplasm due to massive HBsAg accumulation in ER (PAS negative, Orcein positive, Victoria blue stain positive)
• Sanded nuclei: HBcAg in nuclei creates ground-glass nuclear appearance
• Minimal steatosis (unlike HCV)

• Acute symptomatic infection → self-limited recovery (95% of adults)
• Chronic HBV → cirrhosis → HCC (risk 200x higher than uninfected)
• Precore mutant HBV: HBeAg negative but HBV DNA positive (mutant virus cannot produce HBeAg)

---

Hepatitis C Virus (HCV)

• Lymphoid follicles in portal tracts (germinal centers = hallmark)
• Bile duct damage - lymphocytes infiltrating bile duct epithelium (mimics PBC)
• Macrovesicular steatosis - especially genotype 3 (direct viral effect on lipid metabolism)
• Interface hepatitis with lobular activity
• Progression: fibrosis in 20-30 years → cirrhosis → HCC

• Anti-HCV does NOT distinguish acute from chronic or indicate immunity
• False positive anti-HCV: low albumin states (EIA can give false positives)

• No vaccine available (high genetic variability, quasispecies, immune escape)
• Treatment: Direct-acting antivirals (DAAs) → >95% cure rate (SVR = sustained virological response)

---

Hepatitis D Virus (HDV)

---

Hepatitis E Virus (HEV)

---

6. ALCOHOLIC-ASSOCIATED LIVER DISEASE (ALD)

A. Hepatic Steatosis (Alcoholic Fatty Liver)

• Macrovesicular steatosis (large single fat droplet displacing nucleus to periphery) - zone 3 predominance initially
• No significant inflammation
• Reversible on abstinence (weeks)

B. Alcoholic Hepatitis

• Hepatocyte swelling (ballooning degeneration): Swollen hepatocytes with a clear, watery cytoplasm
• Mallory-Denk bodies (Mallory hyaline): Irregular eosinophilic intracytoplasmic inclusions composed of aggregated cytokeratins (CK8 and CK18) + ubiquitin + p62; surrounded by neutrophils (satellitosis = neutrophils surrounding Mallory-Denk body cells)
• Neutrophilic infiltrate (key difference from viral hepatitis where lymphocytes predominate)
• Hepatocyte necrosis (zone 3 predominantly)
• Megamitochondria: Giant eosinophilic mitochondria - reflect mitochondrial injury by acetaldehyde
• Perivenular fibrosis: Chicken-wire fibrosis around central vein (pericellular/sinusoidal fibrosis)

• Fever, leukocytosis, right upper quadrant pain, jaundice
• AST:ALT ratio > 2:1 (often 2:1 to 6:1) - because: alcohol damages mitochondria → releases mitochondrial AST; alcohol depletes vitamin B₆ (PLP) required for ALT synthesis more than AST
• GGT elevated (especially sensitive for alcohol use)
• May precipitate acute-on-chronic liver failure

C. Alcoholic Cirrhosis

• Typically micronodular (Laennec's cirrhosis) - uniform small nodules <3mm
• Deep yellow-green (bile staining), brown (hemosiderin)

• Pericellular/sinusoidal fibrosis ("chicken-wire" pattern) around individual hepatocytes
• Perivenular fibrosis (zone 3 → porta hepatis - reverse of viral hepatitis)
• Micronodular pattern with fibrous septa
• Late stage: mixed or macronodular
• Steatosis may be absent in end-stage (fat oxidized; liver shrunken)

• Spider nevi, palmar erythema, gynecomastia, testicular atrophy (↓ liver metabolism of estrogen)
• Dupuytren's contracture, parotid enlargement
• Leukonychia (white nails)
• Jaundice, ascites, splenomegaly, varices

---

7. METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) / NAFLD

1. MASL (Metabolic-Associated Steatotic Liver) = simple steatosis without inflammation or fibrosis
2. MASH (Metabolic-Associated Steatohepatitis) = steatosis + inflammation + ballooning degeneration ± fibrosis (previously NASH)
3. MASH cirrhosis = end-stage
4. → HCC (even without cirrhosis in some cases)

• Macrovesicular steatosis (panlobular but zone 3 predominant initially)
• Ballooning degeneration of hepatocytes
• Lobular inflammation (mixed - lymphocytes + macrophages + neutrophils)
• Mallory-Denk bodies (less prominent than in alcoholic hepatitis)
• Perisinusoidal fibrosis (zone 3 - "chicken-wire" = pericellular collagen) - characteristic of MASH
• NAS (NAFLD Activity Score): Steatosis (0-3) + Lobular inflammation (0-3) + Ballooning (0-2); NAS ≥5 = MASH

• History: no significant alcohol use (<20 g/day women, <30 g/day men)
• Metabolic risk factors present
• Histologically cannot be reliably distinguished from alcoholic hepatitis (hence the clinical history is essential)

---

8. AUTOIMMUNE HEPATITIS (AIH)

• Type 1 (most common): ANA + ASMA (anti-smooth muscle antibody) ± anti-SLA/LP; any age
• Type 2 (mainly children/teenagers): Anti-LKM-1 (anti-liver kidney microsome 1) + anti-LC1 + anti-SLA/LP

• Plasma cells in clusters (hallmark - not just single plasma cells but aggregates)
• Emperipolesis: Lymphocytes within hepatocyte cytoplasm
• Hepatocyte "rosettes": Circular arrangement of regenerating hepatocytes around dilated canaliculus
• Interface hepatitis (piecemeal necrosis) - extensive
• Confluent necrosis: Perivenular → bridging necrosis → panacinar necrosis (in severe/fulminant cases)
• Fibrosis progressive → cirrhosis at presentation in ~30% of adults
• Burnt-out cirrhosis in some (subclinical disease went unrecognized)

---

9. DRUG/TOXIN-INDUCED LIVER INJURY (DILI)

• Zone 3 → highest CYP2E1 expression → most NAPQI generated
• Risk factors: Fasting (↓ glutathione), chronic alcohol (↑ CYP2E1 + ↓ glutathione), other CYP2E1 inducers

---

10. HEREDITARY HEMOCHROMATOSIS

• Mutation in HFE gene (chromosome 6p21) - most common: C282Y homozygosity (90% of cases); H63D and compound heterozygote
• HFE protein normally downregulates intestinal iron absorption by interacting with transferrin receptor
• Mutant HFE → failure to downregulate iron absorption → net 0.5-1 g/year iron accumulation → symptoms after 20 g stored iron
• Other forms: Juvenile hemochromatosis (HJV or hepcidin mutations - presents at 20s), TfR2 mutations

1. Lipid peroxidation (iron-catalyzed free radical reactions)
2. Stellate cell activation → collagen formation
3. ROS interaction with DNA → increased risk of HCC

• Gross: Liver enlarged, rust-brown color
• Micro: Iron deposited in hepatocytes (periportal, zone 1 predominant initially → all zones), bile duct epithelium, Kupffer cells, pancreas (islets), heart (myocytes), joints (synovium), pituitary, skin
• Prussian blue stain (potassium ferrocyanide) = blue granules = ferric iron (hemosiderin)
• Perls' stain = synonymous
• Micronodular cirrhosis (all symptomatic patients)
• Sideronecrosis: Iron-laden hepatocytes undergoing necrosis

1. Micronodular cirrhosis
2. Diabetes mellitus (75-80%) = "bronze diabetes"
3. Abnormal skin pigmentation (75-80%) = bronze/slate-gray skin (iron + melanin deposition)

---

11. WILSON'S DISEASE

• AR mutation in ATP7B gene (chromosome 13q14) encoding a copper-transporting ATPase in hepatocytes
• ATP7B normally transports copper:
  1. Into the secretory pathway for incorporation into ceruloplasmin (copper-binding protein)
  2. Into bile for excretion

• Early: Fatty change (steatosis); hepatocyte glycogen nuclei (glycogenated nuclei = vacuolated nuclei); mild portal inflammation
• Progressive: Chronic hepatitis pattern → cirrhosis
• Copper staining: Rhodanine stain (orange-red copper deposits) or Orcein stain

• Liver: Steatosis → chronic hepatitis → cirrhosis → acute liver failure (Coombs-negative hemolytic anemia in acute)
• Brain (Basal ganglia): Neuropsychiatric symptoms; "lenticular degeneration" - putamen cavitation; Parkinsonism, dystonia, tremor, psychiatric symptoms
• Eye: Kayser-Fleischer rings (golden-brown copper deposits in Descemet's membrane at corneal periphery) - pathognomonic in right context; seen by slit-lamp examination
• Kidney: Renal tubular acidosis (Fanconi syndrome)
• Blood: Coombs-negative hemolytic anemia during acute liver involvement

---

12. ALPHA-1-ANTITRYPSIN (A1AT) DEFICIENCY

• AR disorder - mutation in SERPINA1 gene
• Most clinically significant mutation: PiZZ genotype (homozygous Z allele) = most common severe deficiency
• Normal A1AT: Pi*MM (PiMM); Heterozygous PiMZ: mild ↓ A1AT
• A1AT normally: serine protease inhibitor (anti-trypsin, anti-elastase) secreted by liver

• Z-allele encodes a misfolded protein → retained in ER → forms polymers (accumulate in hepatocytes) → triggers unfolded protein response → hepatocyte injury + apoptosis
• Simultaneously: ↓ secretion of A1AT into blood → lungs unprotected from neutrophil elastase → panacinar emphysema (especially lower lobes)

• Periodic acid-Schiff (PAS)-positive, diastase-resistant (PAS-D) globules in hepatocyte cytoplasm (zone 1/periportal hepatocytes) = PATHOGNOMONIC finding
• The globules represent misfolded Z-type A1AT protein polymerized in ER (diastase-resistant because they are protein, not glycogen)
• Progression: steatosis → chronic hepatitis → cirrhosis → HCC

• Liver: Neonatal cholestasis (most common cause of neonatal cholestasis in USA), childhood liver disease, cirrhosis in adults
• Lung: Panacinar emphysema (lower lobes) in adults, especially smokers
• Risk of HCC (~35-fold in cirrhotic PiZZ patients)
• Treatment: Augmentation therapy (IV A1AT for lung disease); liver transplant (curative for liver disease and corrects A1AT deficiency because new liver has normal genotype)

---

13. PRIMARY BILIARY CHOLANGITIS (PBC)

• Autoimmune destruction of small intrahepatic bile ducts (interlobular bile ducts <100 µm diameter)
• Predominantly affects middle-aged women (90-95% female); F:M = 10:1
• Associated with other autoimmune conditions (Sjögren's, hypothyroidism, CREST syndrome)

• Anti-mitochondrial antibodies (AMA) - present in 95% of patients; target PDC-E2 (pyruvate dehydrogenase complex E2 subunit) on mitochondrial inner membrane; highly specific; detected by immunofluorescence

• Stage I (Portal stage): Portal inflammation with lymphocytes, plasma cells, eosinophils; florid duct lesion = granulomatous destruction of bile duct (lymphocytes + epithelioid granulomas surrounding bile duct) - pathognomonic
• Stage II (Periportal stage): Periportal hepatitis; ductular proliferation; progressive bile duct loss
• Stage III (Septal stage): Septal fibrosis; bridging fibrosis; progressive bile duct loss
• Stage IV (Cirrhotic stage): Biliary cirrhosis; regenerative nodules surrounded by dense fibrous tissue; copper deposits (secondary to cholestasis - impaired biliary copper excretion)

• Micronodular cirrhosis
• Cholestasis: Bile plugs in canaliculi, bilirubin in hepatocytes
• Periductal xanthomatous change: Foamy lipid-laden macrophages (xanthoma cells) around bile ducts (from cholesterol accumulation due to impaired bile flow)
• Feathery degeneration: Periportal hepatocytes show pale, foamy, "feathery" cytoplasm due to bile salt accumulation

• Insidious onset of pruritus (bile acid accumulation in skin) → fatigue → jaundice
• ↑↑ ALP, ↑ GGT (cholestatic pattern)
• ↑ Serum cholesterol, IgM
• Xanthelasma, xanthomata (cholesterol deposits)
• Osteoporosis (impaired Vit D absorption + ↑ osteoclast activity from bile salt effect)
• Steatorrhea (fat malabsorption - no bile acids reaching gut)
• Treatment: UDCA (ursodeoxycholic acid) (30-40% improvement in biochemistry + slows progression) + obeticholic acid

---

14. PRIMARY SCLEROSING CHOLANGITIS (PSC)

• Inflammation and obliterative fibrosis of intra- and extrahepatic bile ducts of all sizes
• Strong association with IBD (Ulcerative Colitis) in 70% of cases (UC >> Crohn's)
• Male predominance (2:1); 4th-5th decade
• p-ANCA positive in ~80%; AMA negative (differentiates from PBC)

• "Onion-skin" fibrosis: Concentric periductal fibrosis around bile ducts (pathognomonic on biopsy - but biopsy has patchy distribution)
• Progressive fibrosis → bile duct strictures and dilatation → "beaded" appearance on cholangiography (MRCP/ERCP)
• "Pruned tree" appearance on ERCP = alternating strictures and dilations
• Progressive liver fibrosis → biliary cirrhosis
• Loss of bile ducts (ductopenia) in end-stage

• Pruritus, fatigue, jaundice; ↑ ALP, ↑ GGT
• Ascending cholangitis (biliary strictures → bacterial superinfection) - recurrent
• Cholangiocarcinoma - lifetime risk 10-20% (much higher than PBC); often arises at bifurcation (Klatskin tumor)
• Colon cancer: Increased risk due to UC association
• Treatment: Liver transplant (only cure); UDCA controversial; endoscopic dilation of dominant strictures; no effective medical therapy

---

15. HEPATOCELLULAR CARCINOMA (HCC)

Epidemiology

• ~5.4% of all cancers worldwide; 2nd most common cause of cancer death globally
• >85% of cases in Asia and sub-Saharan Africa (high HBV prevalence)
• Marked male predominance (8:1 in high-incidence areas)
• Peak incidence: 20-40 years (Asia) due to perinatal HBV acquisition
• In Western countries: incidence increasing due to MASLD/metabolic syndrome

Etiology and Risk Factors

Pathogenesis

• 15-20% arise in non-cirrhotic liver (especially HBV-related)
• Common driver mutations:
  • TERT promoter mutations (50-60%): ↑ telomerase → immortalization
  • β-catenin (CTNNB1) activating mutations (40%): ↑ Wnt/β-catenin signaling → proliferation
  • TP53 inactivating mutations (up to 60%): Loss of p53 tumor suppressor; in aflatoxin-related HCC: specific G→T transversion at codon 249
  • PI3K/AKT/mTOR pathway mutations
  • RAS/MAPK pathway activations

• Adolescents and young adults, NO preexisting liver disease
• DNAJB1::PRKACA fusion gene → excessive protein kinase A activity
• Better prognosis than classic HCC; no elevated AFP
• Gross: Single large tumor with fibrous bands (lamellar = sheet-like)

Precursor Lesions

• Large cell change: Hepatocytes larger than normal, enlarged/pleomorphic nuclei, no ↑ N:C ratio
• Small cell change: High N:C ratio, mild nuclear hyperchromasia → more ominous precursor
• Dysplastic nodules (Low-grade and High-grade) → high-grade = immediate HCC precursor

Morphology

• Single large mass, multiple nodules, or diffuse infiltrative growth (especially in cirrhosis)
• Typically soft, pale tan to yellow-green, vascular (highly vascular tumor - arterial)
• Bile-stained (bile production by tumor cells = only tumor that makes bile)
• Characteristic of HCC: invasion into portal vein / hepatic veins (portal vein tumor thrombus)

• Cells resembling hepatocytes (trabecular, pseudoglandular, or acinar patterns)
• Abundant eosinophilic cytoplasm, bile canaliculi between cells
• Prominent nucleoli
• Immunohistochemistry: AFP (alpha-fetoprotein) positive; Hep Par-1 positive; Arginase-1 positive; CK8/18 positive
• Tumor cells: CK7 negative, CK20 negative (helps distinguish from metastatic adenocarcinoma)

• AFP (Alpha-fetoprotein) elevated in ~70% of HCC
  • Normal serum AFP: <10-15 ng/mL
  • AFP >400 ng/mL in at-risk patient with liver mass = diagnostic
  • AFP can also be elevated in: other liver diseases, yolk sac tumors (testicular/ovarian)
• PIVKA-II (Des-γ-carboxyprothrombin) = sensitive and specific marker; used in Asia

Surveillance

• 6-monthly ultrasound ± AFP in cirrhotic patients and HBV carriers with high risk factors
• Contrast CT/MRI: arterial phase enhancement + portal venous washout = LI-RADS 5 = HCC (no biopsy needed for classic pattern)

---

16. CHOLANGIOCARCINOMA (CCA)

• Malignant neoplasm derived from cholangiocytes (bile duct epithelium)

• Dense desmoplastic reaction (abundant fibrous stroma → hard scirrhous tumor)
• Gland-forming mucin-secreting adenocarcinoma
• IHC: CK7 positive, CK19 positive, CK20 negative (intrahepatic CCA); AFP negative; CA 19-9 elevated (serum)

• Jaundice (obstructive - perihilar, distal); or incidental liver mass (intrahepatic)
• Poor prognosis (most unresectable at diagnosis)
• Perihilar CCA: biliary stenting; liver transplant in select PSC patients with perihilar CCA

---

17. VASCULAR DISORDERS OF THE LIVER

Budd-Chiari Syndrome (Hepatic Vein Outflow Obstruction)

• Thrombosis or occlusion of hepatic veins (±IVC)
• Causes: Polycythemia vera (most common), hypercoagulable states, oral contraceptives, pregnancy, myeloproliferative disorders, paroxysmal nocturnal hemoglobinuria, Behçet's disease, membranous webs of IVC (in Asia/Africa)
• Morphology:
  • Gross: Liver enlarged, congested, purple-red
  • Micro: Severe centrilobular congestion (zone 3) → zone 3 hepatocyte necrosis → fibrosis → "congestive cirrhosis"
  • Caudate lobe hypertrophy (pathognomonic): Caudate lobe drains directly into IVC independently → spared from venous obstruction → compensatory hypertrophy (visible on imaging)
• Clinical: Acute: abdominal pain, hepatomegaly, ascites; Chronic: progressive cirrhosis; some present with fulminant hepatic failure

Cardiac Hepatopathy (Congestive Heart Failure)

• Chronically elevated central venous pressure → hepatic venous congestion
• Morphology: "Nutmeg liver" (gross) = red centrilobular congestion (zone 3) contrasting yellow periportal parenchyma (fattyl change)
• Micro: Zone 3 hepatocyte necrosis → "cardiac cirrhosis" (rare, but possible in long-standing CHF)
• Centrilobular fibrosis pattern (unlike other forms of cirrhosis which start in portal tracts)

Sinusoidal Obstruction Syndrome (SOS) / Hepatic Veno-Occlusive Disease (HVOD)

• Obstruction at sinusoidal and centrilobular venule level (NOT hepatic vein thrombosis)
• Causes: High-dose chemotherapy (busulfan, cyclophosphamide) before bone marrow transplant; pyrrolizidine alkaloids (herbal teas, Jamaican "bush tea"); radiation
• Endothelial cell damage → edema → fibrin deposition → sinusoidal and centrilobular venule narrowing
• Morphology: Zone 3 congestion and necrosis without hepatic vein thrombosis; centrilobular fibrosis

Portal Vein Thrombosis (PVT)

• Extrahepatic PVT causes: Cirrhosis (50%), intra-abdominal inflammation (appendicitis, peritonitis), malignancy (HCC invades portal vein), coagulation disorders
• Results in: Portal hypertension with splenomegaly; can form cavernous transformation (collateral vessels around thrombosed portal vein = cavernoma)
• Acute PVT: may cause bowel ischemia if SMV involved

---

18. BENIGN LIVER TUMORS

---

19. SUMMARY TABLE - KEY HISTOLOGICAL FINDINGS IN LIVER PATHOLOGY

---

---

• Microbiology (Hepatitis viruses in detail - Jawetz + Murray)
• Pharmacology (Antivirals, drugs for complications - Goodman & Gilman + Katzung)
• Medicine (Clinical management - Harrison's 22nd Ed)
• Surgery (Hepatic resection, portal hypertension surgery - Schwartz/Sabiston)

---

MICROBIOLOGY OF THE LIVER - Full Textbook-Level Notes

---

OVERVIEW: THE FIVE HEPATOTROPIC VIRUSES

---

1. HEPATITIS A VIRUS (HAV)

Taxonomy and Structure

• Family: Picornaviridae, genus: Hepatovirus (only hepatotropic picornavirus)
• Particle: 27-32 nm, spherical, icosahedral capsid (non-enveloped)
• Genome: Positive-sense ssRNA, 7.5 kb, linear; single open reading frame
• One serotype (only one; cross-protective immunity worldwide)
• Seven genotypes (I-VII) based on variable sequence at 1D/2A junction; genotype I is most prevalent in humans
• Proteins: VP1, VP2, VP3, VP4 = capsid; VPg = genome-linked protein; 2Apro/3Cpro = proteases; 3Dpol = RNA-dependent RNA polymerase

Resistance to Physical/Chemical Agents (Jawetz)

• Stable at: pH 1.0 for 2 hours; 20% ether; 60°C for 1 hour; -20°C storage for years
• Destroyed by: Autoclaving (121°C, 20 min); boiling for 5 min; dry heat 180°C; UV irradiation (1 min at 1.1 W); formalin (1:4000, 3 days at 37°C); chlorine (10-15 ppm, 30 min); sodium hypochlorite 1:100
• Heating food to >85°C for 1 minute inactivates HAV
• Practical implication: Normal household disinfectants may be insufficient; bleach required for contaminated surfaces

Receptor and Cell Entry

• HAVcr-1 (TIM-1/KIM-1) on hepatocyte surface is the primary receptor for cell entry
• HAV has a very limited cell tropism (essentially only hepatocytes)
• In vitro: Various primate cell lines support replication, but no cytopathic effects; slow adaptation required for fresh isolates

Replication and Pathogenesis

• HAV replicates in the cytoplasm of hepatocytes
• Shed in bile → high concentrations in feces (peak infectivity in last 2 weeks of incubation period and first week of symptoms)
• NOT cytopathic directly - liver injury is immunologically mediated:
  • Cytotoxic T lymphocytes (CTL/CD8+) recognize HAV antigens on hepatocyte surface → hepatocyte lysis
  • NK cells contribute to early non-specific killing
  • Interferon (IFN-α/β) production by infected cells limits viral spread
• After symptoms appear, viral shedding falls rapidly (humoral immunity clears virus)

Clinical Course

1. Incubation: 15-50 days (mean 28 days)
2. Prodromal phase (pre-icteric, 1-2 weeks): Fever, malaise, anorexia, nausea, RUQ discomfort; dark urine; liver tender on palpation
3. Icteric phase: Jaundice appears (if symptomatic); liver enlargement; most adults are icteric; children often anicteric/subclinical
4. Convalescence: 1-3 months; complete recovery

• No chronicity (no persistent infection)
• Fulminant hepatitis (massive hepatic necrosis): 0.1-0.3%; higher risk in patients with pre-existing liver disease (chronic HBV, HCV, cirrhosis)
• Relapsing hepatitis: 10-15% have a second wave of disease after apparent recovery - self-limited
• Cholestatic hepatitis: Prolonged cholestasis with pruritus; responds to corticosteroids

Serology and Diagnosis (Murray)

• Anti-HAV IgM: Appears at onset of symptoms; persists 3-6 months → diagnosis of acute infection
• Anti-HAV IgG: Appears weeks after IgM; persists lifelong → indicates past infection or vaccination → marker of immunity
• Stool HAV antigen: Detectable 1-2 weeks before and up to 1-2 weeks after onset of symptoms
• HAV RNA by RT-PCR: Most sensitive; used in outbreak investigation and blood safety screening

Prevention

• Inactivated HAV vaccine (Havrix, Vaqta): 2 doses, 6-12 months apart; nearly 100% efficacy; long-lasting immunity
• Immunoglobulin (IG): Post-exposure prophylaxis within 2 weeks of exposure; also used for travelers to endemic areas if too close to departure for vaccine
• Vaccine + IG: For highest-risk exposed individuals
• Sanitation: Proper sewage disposal, safe water supply, hand hygiene; HAV survives on environmental surfaces

---

2. HEPATITIS B VIRUS (HBV)

Taxonomy and Structure (Murray + Jawetz)

• Family: Hepadnaviridae (Hepatitis DNA viruses); Genus: Orthohepadnavirus
• Animal relatives: Woodchuck hepatitis virus (WHV), Ground squirrel hepatitis virus (GSHV), Duck hepatitis B virus (DHBV) - all have limited host ranges; useful animal models
• Dane particle: Complete 42 nm virion; most complex hepatitis virus
  • Outer lipid envelope containing three forms of HBsAg (S, M, L)
  • Inner 27 nm icosahedral nucleocapsid (HBcAg)
  • Inside core: partially double-stranded circular DNA genome, 3200 bp (3.2 kb); covalently closed circular DNA (cccDNA) in nucleus; reverse transcriptase (RT/RNase H = P protein)
• HBsAg particles in serum: Two additional non-infectious forms produced in massive excess:
  • 22 nm spheres (most abundant - 10,000× excess over Dane particles): composed of HBsAg S protein; not infectious; immunogenic → used for original plasma-derived vaccine
  • Filamentous/tubular forms (22 nm diameter, >200 nm long): S, M, L HBsAg
  • These excess HBsAg particles serve as decoys for the immune system

HBsAg Proteins (Murray)

• S protein (gp27/24-27 kDa): Small; main component of 22-nm particles; completely contained within M and L
• M protein (gp36/33-36 kDa): Medium; contains preS2 + S
• L protein (gp42/39-42 kDa): Large; contains preS1 + preS2 + S; essential for viral attachment to hepatocytes (preS1 binds NTCP = sodium-taurocholate co-transporting polypeptide on hepatocyte membrane)

Genome Organization - 4 Open Reading Frames (ORFs)

HBV Replication Cycle (Jawetz - crucial for antiviral targets)

1. Attachment: L-HBsAg (preS1 domain) binds NTCP (SLC10A4) on hepatocyte - the functional receptor identified in 2012
2. Fusion: Viral envelope fuses with hepatocyte membrane → nucleocapsid enters cytoplasm
3. Nuclear transport: Core particle transported to nucleus → releases genome
4. cccDNA formation: Partially double-stranded DNA → host enzymes repair to form covalently closed circular DNA (cccDNA) - the viral "minichromosome" - template for all viral RNAs; persists lifelong in hepatocyte nucleus; cannot be eradicated by current antivirals
5. Transcription: cccDNA → four viral mRNAs (by host RNA polymerase II):
   • 3.5 kb pregenomic RNA (pgRNA) - most important: packaged in new cores; serves as template for reverse transcription
   • 2.4 kb, 2.1 kb (for HBsAg forms), 0.7 kb (for HBx)
6. Packaging: pgRNA + P protein + cellular proteins → packaged into new cores (by HBcAg)
7. Reverse transcription (by P protein) inside core:
   • P protein primes its own reverse transcription using a 5' hairpin of pgRNA as template → negative-strand DNA
   • RNase H activity of P degrades the pgRNA template
   • Positive-strand DNA synthesis (incomplete → partially ds DNA = mature genome)
8. Envelopment: Mature core buds through ER/Golgi acquiring HBsAg envelope → secreted as Dane particle
   • OR core re-enters nucleus → amplifies cccDNA pool
9. cccDNA persistence: 5-50 copies per cell; responsible for viral persistence and rebound after stopping antivirals

HBV Stability

• Unusually stable for an enveloped virus - resists ether, low pH, freezing, moderate heating
• Infectious on surfaces at room temperature for ≥7 days
• HBV is NOT readily inactivated by detergents (unlike most enveloped viruses)
• Disinfect with 10% bleach; autoclave for instruments

HBV Antigens, Antibodies, and Serology - Complete

HBV Genotypes

• 10 genotypes (A-J) based on >8% nucleotide divergence
• Clinically relevant:
  • Genotype A: Europe, North America; responds better to pegylated interferon
  • Genotype B, C: Asia; Genotype C associated with higher HCC risk
  • Genotype D: Mediterranean, India; more resistance mutations

Precore Mutant HBV

• Mutation in precore region (stop codon at codon 28: G1896A) → cannot produce HBeAg
• HBeAg-negative, anti-HBe positive, but HBV DNA positive (ongoing active replication)
• More aggressive disease; common in Mediterranean (genotype D), Asia (genotype B/C)
• More relapses on antiviral therapy

Pathogenesis of Liver Injury

• HBV is NOT directly cytopathic at low-to-moderate levels of replication
• Liver injury is primarily immunologically mediated:
  • CD8+ CTLs recognize HLA class I + viral peptides on hepatocyte surface → hepatocyte lysis
  • CD4+ T helper cells (recognizing HBcAg/HBeAg peptides) amplify the immune response
  • In immunocompetent adults: vigorous immune response → symptomatic hepatitis BUT effective viral clearance (95%)
  • In neonates: immature immune response → no effective clearance → chronic infection (90%) with minimal acute liver injury
  • In chronic infection: persistent lower-level immune response → continuous hepatocyte turnover → cirrhosis → HCC
• HBx protein plays a direct carcinogenic role: activates oncogenes (c-myc, c-fos), inhibits TP53, activates Ras/MAPK and Wnt/β-catenin pathways
• HBV DNA integrates into host genome in chronic infection → insertional mutagenesis → additional HCC risk

Prevention and Vaccines

• Recombinant HBsAg vaccine (Engerix-B, Recombivax HB): S gene expressed in Saccharomyces cerevisiae → HBsAg self-assembles into 20-nm VLPs → alum adjuvant
  • 3-dose series (0, 1, 6 months): >95% seroconversion
  • Universal infant vaccination (neonatal dose within 12-24h if mother HBsAg+) - critical for interrupting perinatal transmission
• Heplisav-B (third-generation): Yeast-derived HBsAg + CpG-ODN (TLR-9 agonist) adjuvant → only 2 doses, 1 month apart; better immunogenicity
• HBIG (Hepatitis B Immune Globulin): Passive immunization; for post-exposure prophylaxis (needlestick, perinatal exposure); given within 24h; combined with vaccine for neonates of HBsAg+ mothers

---

3. HEPATITIS C VIRUS (HCV)

Taxonomy and Structure (Murray + Jawetz)

• Family: Flaviviridae, genus: Hepacivirus (only member of this genus)
• Particle: 30-60 nm, enveloped, spherical
• Genome: Positive-sense ssRNA, 9.4 kb; single long open reading frame (polyprotein precursor)
• The genome encodes 10 proteins (3 structural + 7 non-structural):
  • Structural: Core (nucleocapsid protein, C), E1 glycoprotein, E2 glycoprotein
  • Non-structural: p7 (ion channel/viroporin), NS2, NS3 (serine protease + helicase/NTPase), NS4A (NS3 cofactor), NS4B, NS5A (membranous web formation, replication complex), NS5B (RNA-dependent RNA polymerase - RdRp)

HCV Genome Organization

5'UTR - C - E1 - E2 - p7 - NS2 - NS3 - NS4A - NS4B - NS5A - NS5B - 3'UTR
             Structural            |           Non-structural

• 5' UTR: Contains IRES (internal ribosome entry site) - cap-independent translation
• E1, E2: Highly variable envelope glycoproteins; hypervariable region 1 (HVR-1) of E2 = main target of neutralizing antibodies → rapid mutation → immune escape → explains why vaccine development is so difficult
• NS3 protease: Target of first-generation DAAs (boceprevir, telaprevir; now superseded by NS3/4A inhibitors like simeprevir, grazoprevir, voxilaprevir)
• NS5A: Target of NS5A inhibitors (daclatasvir, ledipasvir, velpatasvir, pibrentasvir)
• NS5B (RdRp): Target of nucleotide analog NS5B inhibitors (sofosbuvir)

HCV Entry Receptors

• CD81 (tetraspanin): Primary receptor for E2
• SR-B1 (Scavenger Receptor class B type I): Binds E2
• Claudin-1, Occludin: Tight junction proteins used as co-receptors (post-attachment entry)
• LDLR (LDL receptor): HCV coats itself with VLDL/LDL (lipoviroparticle) → entry via lipoprotein receptor
• This multi-receptor strategy makes receptor-targeted therapy very difficult

HCV Genotypes

• 7 major genotypes (clades/1-7) and >100 subtypes
• Clades differ from each other by 25-35% at nucleotide level; subtypes by 15-25%
• Within each infected patient: quasispecies = swarm of closely related but slightly different sequences generated by NS5B error-prone replication → rapid selection for drug resistance mutations; helps explain immune evasion

HCV Replication

• Entry (as above) → cytoplasmic RNA translation via IRES → polyprotein (3011 AA) → processed by NS2-NS3 viral protease + host signal peptidase → all 10 proteins
• Replication complex forms on membranous web (endoplasmic reticulum-derived) = "membranous web" = assembled by NS4B
• NS5B replicates RNA genome through negative-strand intermediate (no DNA; no cccDNA → different from HBV; can be cured)
• Assembly at ER → budding into ER lumen → transit through Golgi → secreted as enveloped virion
• No nuclear phase; no cccDNA → explains why cure (SVR) is achievable with DAAs

Clinical Course of HCV

• Most new infections (70-80%) are subclinical (no symptoms or mild non-specific illness)
• Acute symptomatic phase: Mild, non-specific (malaise, nausea); jaundice in <25%
• Chronicity: 70-90% fail to clear → chronic HCV
  • 20-30% of chronic HCV → cirrhosis over 20-30 years
  • Of those with cirrhosis: ~2-4% per year risk of HCC
• Extrahepatic manifestations (immunological, from immune complex deposition):
  • Mixed cryoglobulinemia (Type II - monoclonal RF + polyclonal IgG) → vasculitis, glomerulonephritis, purpura, arthralgias
  • Membranoproliferative glomerulonephritis (MPGN)
  • B-cell non-Hodgkin's lymphoma (HCV drives B cell proliferation via CD81)
  • Porphyria cutanea tarda (PCT)
  • Autoimmune thyroiditis; Sjögren's-like syndrome; lichen planus

Diagnosis

• Anti-HCV ELISA (3rd generation): Screening test; detects antibodies to multiple HCV antigens (core, NS3, NS4, NS5); does NOT distinguish acute, chronic, or cleared infection; false negatives in acute infection (window period up to 8-12 weeks after exposure)
• HCV RNA by RT-PCR (quantitative/qualitative): Confirms active infection; measures viral load; monitors treatment response
  • Qualitative: limit of detection ~10-15 IU/mL
  • Quantitative: expressed as IU/mL; correlates with treatment response
• HCV core antigen assay: Detectable earlier than anti-HCV; correlates with viral load; useful where PCR unavailable
• HCV genotyping: Guides choice of DAA regimen and treatment duration
• Liver fibrosis assessment: FIB-4 score, FibroScan (transient elastography), or liver biopsy (Metavir staging F0-F4)

No Vaccine

• High mutation rate of E1/E2 (hypervariable region) → no cross-protective immune response to different quasispecies
• Over 100 subtypes; immune response to one does not protect against another
• Multiple DAAs now achieve >95% SVR → focus on treatment as prevention

---

4. HEPATITIS D VIRUS (HDV)

Structure and Unique Biology (Murray + Jawetz)

• Defective RNA virus - an "obligate parasite" of HBV
• Particle: 35-37 nm; has its own antigen (HDAg = delta antigen) but borrows HBsAg as its outer envelope
• Genome: Circular, negative-sense ssRNA ~1700 nucleotides (smallest animal virus genome); resembles plant viroid or satellite RNA
• HDV RNA is self-complementary (rod-like secondary structure) → resembles plant viroids
• HDAg: Two forms - small HDAg (p24) promotes replication; large HDAg (p27) inhibits replication and is required for assembly (addition of prenylation signal)
• Replication: Uses host RNA polymerases (hijacks cellular Pol II and Pol I for replication) → no viral RNA polymerase encoded

HDV and HBV Dependence

• HDV absolutely requires HBsAg for:
  1. Its own envelope (wraps its nucleoprotein in HBsAg coat)
  2. Cell entry (preS1 domain of HBsAg binds NTCP)
• Therefore:
  • HDV only infects individuals already infected with HBV
  • HBV vaccination prevents HDV (if no HBV, no HDV)
  • HBV antivirals that suppress HBsAg may reduce HDV replication

Forms of HDV Infection

1. Co-infection (HDV + HBV simultaneously, both acute):
   • Presents as severe acute hepatitis with biphasic transaminase elevation (two peaks)
   • Usually self-limited (only 5-10% chronic); immune system clears both viruses together
   • Risk of fulminant hepatic failure higher than HBV alone
2. Superinfection (acute HDV infecting a chronic HBV carrier):
   • 90-100% chronic HDV
   • Accelerated progression to cirrhosis; higher risk of fulminant hepatitis
   • 5-10 years earlier development of cirrhosis compared to HBV alone
   • Worst prognosis of any hepatitis combination

Diagnosis

• Anti-HDV IgM and IgG: ELISA; IgM indicates active HDV
• HDV RNA by PCR: Quantitative; most sensitive; best for monitoring
• HDAg in liver: Immunostaining; nuclear predominance

---

5. HEPATITIS E VIRUS (HEV)

Taxonomy and Structure

• Family: Hepeviridae, genus: Orthohepevirus; previously incorrectly classified with Caliciviruses
• Particle: 27-34 nm, spherical, non-enveloped (naked capsid, like HAV)
• Genome: Positive-sense ssRNA, 7.2 kb; 3 open reading frames:
  • ORF1: Non-structural proteins (methyltransferase, helicase, RdRp)
  • ORF2: Capsid protein (viral antigen; target of antibody)
  • ORF3: Small multifunctional protein (involved in virion release)

HEV Genotypes and Epidemiology

• HEV-1 and HEV-2: Epidemic; waterborne; developing countries; major outbreaks after flooding (India, Bangladesh, Pakistan, Myanmar, Nepal, Sudan)
• HEV-3 and HEV-4: Zoonotic; sporadic; developed countries; pigs are the main reservoir

Clinical Features

• Incubation: 15-50 days
• Acute, self-limited hepatitis; clinically indistinguishable from HAV in most patients
• Special risk: pregnant women (especially 3rd trimester):
  • HEV-1 infection → fulminant hepatitis in 20-25% of pregnant women
  • Mechanism: hormonal immune modulation in pregnancy (elevated progesterone suppresses Th1 responses) + placental HEV replication → vertical transmission → fetal infection + spontaneous abortion
  • This is unique to HEV-1 (HEV-3 is much less virulent in pregnancy)
• Chronic HEV: Only in immunocompromised hosts (solid organ transplant recipients, HIV patients with CD4 < 200, hematologic malignancies on chemotherapy):
  • HEV-3 and HEV-4 responsible
  • May lead to rapid progression to cirrhosis (within 2-3 years) if untreated
  • Treatment: Reduce immunosuppression; ribavirin (12-24 weeks; cure rate ~80%)
• Extrahepatic: HEV associated with neurological manifestations (Guillain-Barré syndrome, neuralgic amyotrophy/brachial neuritis, meningitis)
• HEV-3 in pig slaughterhouse workers → occupational exposure

Diagnosis

• Serum anti-HEV IgM (acute)
• Serum anti-HEV IgG (past infection/immunity)
• HEV RNA by RT-PCR (blood or stool): most sensitive in early acute phase; essential for diagnosis in immunocompromised (serology may be negative due to impaired antibody response)

HEV Vaccine

• Hecolin (HEV 239): Recombinant capsid protein vaccine; licensed and used in China (2012); highly efficacious
• Not yet universally available in most countries (as of 2026)

---

6. HEPATITIS G VIRUS (HGV/GBV-C)

• Flavivirus related to HCV; now called GBV-C (GB virus C)
• Transmitted parenterally; common in blood donors
• Despite early concern, HGV/GBV-C does NOT cause hepatitis
• May actually have a protective effect against HIV progression (immune modulation)
• No treatment required; largely of historical/research interest

---

PART B: NON-VIRAL MICROBIOLOGY OF THE LIVER

---

7. HEPATIC PARASITES - TREMATODES (FLUKES)

A. Clonorchis sinensis (Chinese Liver Fluke) - Sherris 8e

• Phylum Platyhelminthes, Class Trematoda
• Related flukes: Opisthorchis viverrini (Southeast Asia - Thailand, Laos), Opisthorchis felineus (Eastern Europe), Fasciola hepatica (sheep liver fluke - worldwide)

• Small, flat, leaf-shaped adult worm: 5 × 15 mm
• Cone-shaped anterior pole; large oral sucker + ventral sucker
• Two deeply lobular testes in posterior third (distinguishing feature)
• Hermaphroditic
• Eggs: 15 × 30 µm (tiny = smallest helminth egg in clinical practice); urn-shaped with opercular rim (shoulder at junction) + posterior knob; yellow-brown, refractile

1. Definitive host (humans, cats, dogs, rats, pigs): Adult worms live in intrahepatic bile ducts for up to 50 years; produce ~2000 eggs/day → eggs exit in bile → pass in feces
2. First intermediate host (freshwater snail): Eggs ingested → miracidium → sporocyst → redia → cercariae → released into water
3. Second intermediate host (freshwater fish): Cercariae penetrate fish tissues → encyst as metacercariae (infective stage for humans)
4. Human infection: Eating raw, undercooked, fermented, dried, salted, or pickled freshwater fish → metacercariae released in duodenum → ascend common bile duct → reach second-order intrahepatic bile ducts → mature to adults over 30 days

• Endemic in: Korea, Japan, Taiwan, Red River Valley of Vietnam, Guangdong province (China), Hong Kong
• Up to 35 million infected worldwide
• Entire adult population may be infected in some Chinese villages
• Perpetuated by fertilizing fish ponds with human feces (improving sanitation → decreasing prevalence, but slowly due to long lifespan)

• Adult worm in bile duct → feeds on biliary mucosal secretions → induces epithelial hyperplasia, adenoma formation, periductal inflammation
• Light infections: usually asymptomatic
• Heavy infections (worm loads 500-1000 from repeated reinfection):
  • Bile stone formation (dead worm fragments + bile pigments)
  • Biliary obstruction → secondary bacterial cholangitis → bacteremia/endotoxemia
  • Asymptomatic biliary carriage of Salmonella Typhi (worms harbor bacteria in bile ducts)
  • Occasional extension into pancreatic ducts → pancreatitis
  • Cholangiocarcinoma (most important long-term complication) - WHO Group 1 carcinogen
    • Mechanism: chronic biliary epithelial irritation → metaplasia → dysplasia → malignancy
    • Opisthorchis viverrini carries the highest cholangiocarcinoma risk of all liver flukes

• Stool microscopy: identify characteristic eggs (shoulder + posterior knob)
• Duodenal aspirate: more sensitive
• Serology: ELISA (less specific due to cross-reactivity)
• Imaging (US/CT): dilated intrahepatic bile ducts; filling defects

• Praziquantel (single dose 40 mg/kg or 75 mg/kg in 3 divided doses): drug of choice; >95% efficacy

---

B. Fasciola hepatica (Sheep Liver Fluke)

• Large fluke: 3 × 1.5 cm (largest trematode to infect humans)
• Distribution: Worldwide (especially Mediterranean, South America, Africa, Asia)
• Life cycle: Definitive hosts = sheep, cattle, humans; snail intermediate host; watercress/aquatic plants as vehicles of metacercariae
• Acute phase: Young flukes migrate from gut through peritoneal cavity → liver capsule → parenchyma → bile ducts → fever, RUQ pain, hepatomegaly, eosinophilia (marked, often >3000/µL)
• Chronic phase: Adults in large bile ducts → biliary obstruction, cholangitis, bile duct fibrosis; rare cholangiocarcinoma (much less than Clonorchis)
• Eggs: Large (130-150 × 60-90 µm), yellow-brown, operculated; passed in feces
• Diagnosis: Stool microscopy; serology (ELISA - highly sensitive); imaging (liver "tracking lesions" on CT)
• Treatment: Triclabendazole (drug of choice; praziquantel NOT effective for Fasciola); nitazoxanide (alternative)

---

8. HEPATIC PARASITES - CESTODES (TAPEWORMS)

Echinococcus granulosus - Hydatid Cyst Disease (Sherris 8e)

• Phylum Platyhelminthes, Class Cestoda
• Species: E. granulosus (cystic echinococcosis) and E. multilocularis (alveolar echinococcosis)

• Smallest tapeworm to cause human disease: only 3-5 mm total length
• Lives in small bowel of dogs, wolves, foxes for ~12 months
• Scolex: 4 sucking disks + double row of hooklets (armed scolex = differentiates from Taenia)
• Only 3 proglottids: 1 immature + 1 mature + 1 gravid
• Gravid proglottid splits → releases eggs (morphologically identical to Taenia eggs: hexacanth embryo inside)

1. Definitive host (dog): Harbors adult worms in small bowel; passes eggs in feces
2. Intermediate hosts (sheep, goats, camels, deer - normally; humans accidentally): Ingest eggs from contaminated soil/water/food
3. Egg hatching: Hexacanth embryo hatches in duodenum → penetrates intestinal mucosa → enters portal blood → transported to liver (where most are trapped in sinusoids)
4. Larval development: Survivors form hydatid cyst:
   • Outer laminated cuticle (acellular, white, lamellar)
   • Inner germinal layer (nucleated; produces brood capsules, protoscolices, daughter cysts, hydatid sand)
   • Cyst fills with fluid (antigenic, anaphylactogenic)
   • Growth: 1 cm over first 5-6 months → can reach >10 cm over years
   • Contains "daughter cysts" (internal secondary cysts from germinal layer)
   • "Hydatid sand": Degenerated protoscolices + germinal membrane fragments at bottom of cyst
5. Organ distribution: Most lodge in liver (65%); next in lungs (25%); then brain, heart, bones, kidney (≤10% total)
6. Cycle completion: Only when intermediate host (infected sheep) is eaten by a dog → scolices released → develop to adults

• Slowly expanding space-occupying lesion
• Compression of adjacent liver/biliary structures
• Rupture (spontaneous or traumatic): Sudden release of antigenic cyst fluid → anaphylaxis (can be fatal); spillage of protoscolices → secondary implantation = "seeding" → multiple new cysts throughout abdomen
• Secondary bacterial infection → pyogenic liver abscess on top of hydatid cyst

• Often asymptomatic for years (slow growth)
• RUQ discomfort, hepatomegaly when cyst large
• Obstructive jaundice (biliary compression/communication)
• Rupture: Sudden intense abdominal pain + urticaria/anaphylaxis (cyst fluid = anaphylactogenic)
• Biliary communication: Cyst ruptures into bile duct → obstructive jaundice; biliary colic; bacterial superinfection; cholangitis; daughter cysts/membranes passed per rectum (pathognomonic if seen)
• Serology: ↑ serum IgE; eosinophilia (variable)
• Casoni test (intradermal): Historical; not used now

• Adult in foxes (not dogs); intermediate hosts = small rodents; humans accidental
• More aggressive: larval cysts invade liver as alveolar (honeycomb) structure without a defined cyst wall → infiltrates liver like a malignancy → "parasitic cancer"
• Much harder to treat; high mortality if untreated
• Distribution: Northern latitudes (Alaska, Canada, Siberia, Central Europe, China)

• Imaging (US/CT): "Water lily sign" (collapsed membranes floating in cyst fluid); daughter cysts; calcified rim; pathognomonic finding = double-line sign (two wall layers) on US
• Serological tests: ELISA for anti-Echinococcus antibodies (~85% sensitivity for hepatic cysts; lower for other organs)
• Casoni skin test: historical
• NEVER aspirate blindly → risk of spillage + anaphylaxis
  • Exception: PAIR procedure (Puncture-Aspiration-Injection-Reaspiration) by expert hands with cover of albendazole

• Surgical resection: Traditional gold standard; requires intact cyst removal (no spillage); preceded by injection of scolicidal agent (hypertonic saline, cetrimide, ethanol)
• PAIR procedure: Minimally invasive alternative; requires albendazole cover before and after
• Albendazole (benzimidazole): Medical therapy alone for inoperable cases; also adjunct to surgery/PAIR; reduces cyst viability; given in 28-day cycles with 14-day breaks

---

9. HEPATIC PARASITES - PROTOZOA

A. Entamoeba histolytica - Amebic Liver Abscess

• 500 million infected worldwide; 50 million develop invasive disease; 100,000 deaths/year
• Endemic in: India, Southeast Asia, Central and South America, Africa, Mexico
• Transmission: Fecal-oral (cysts in contaminated food/water)
• Most infections remain in the gut; only ~10% develop invasive disease
• Amebic liver abscess (ALA): Most common extraintestinal manifestation; more common in males (10:1) due to unknown reasons (possibly hormonal - testosterone ↑ susceptibility; estrogen protective)

• Two forms: Trophozoite (pathogenic, motile, 20-40 µm, ingests RBCs = erythrophagocytosis = hallmark) and Cyst (infective, 12-15 µm, 4 nuclei, resistant)
• Cyst ingested → trophozoites released in large intestine → colonization of colon → invasion through mucosa → trophozoites enter portal circulation → travel to liver → form abscess

• Trophozoites produce: cysteine proteases (degrade extracellular matrix, cleave IgA/IgG), amoebapores (form pores in cell membranes → cell lysis), phospholipase A2
• Trophozoites lyse hepatocytes → liquefaction → "anchovy paste" or "chocolate sauce" pus (actually necrotic liver tissue + trophozoites; no real pus = sterile unless secondary bacterial infection)
• ALA = usually single (right lobe, 80%) large abscess; fluid is reddish-brown ("chocolate"/"anchovy paste")
• Trophozoites seen at abscess periphery (not in the necrotic center)
• Secondary bacterial superinfection: 3-5% of cases → frank pus

• Fever + RUQ pain + tender hepatomegaly = classic triad
• High fever (>39°C), sweating
• Minimal GI symptoms (only 30-40% have concurrent dysentery)
• RUQ tenderness; may have referred right shoulder pain (diaphragmatic irritation)
• Complications:
  • Rupture into pleural cavity (right-sided pleural effusion, empyema): most common complication
  • Rupture into pericardium (rare but life-threatening - cardiac tamponade): Left lobe ALA
  • Rupture into peritoneum → peritonitis
  • Rupture into bronchus → hepatobronchial fistula → patient coughs up "chocolate sauce" (pathognomonic)

• Serology (anti-amoeba IgG ELISA): >95% sensitivity for ALA; persists for years (cannot distinguish active from past infection in endemic areas)
• Aspiration of abscess: "Anchovy paste"/"chocolate sauce"; sterile; amoebic trophozoites rarely found in aspirate (at periphery)
• Stool O&P microscopy: Cysts or trophozoites; positive in only 30-40% of ALA cases
• Stool antigen test (ELISA for Gal/GalNAc lectin): More sensitive than microscopy
• Stool PCR: Most sensitive
• Imaging: Ultrasound = best initial test (round/oval hypodense lesion, right lobe); CT = confirms and characterizes
• Distinguish from pyogenic abscess: ALA = single, large; pyogenic = multiple, smaller

• Metronidazole (or tinidazole): 750 mg TID × 5-10 days; kills trophozoites; highly effective
• Followed by a luminal amebicide (paromomycin 25-35 mg/kg/day × 7 days; or iodoquinol): to eradicate intestinal cysts and prevent reinfection
• Aspiration: For large cysts (>10 cm), left lobe ALA (high rupture into pericardium risk), non-response to metronidazole, secondary bacterial superinfection; diagnostic aspiration to rule out pyogenic abscess

---

10. HEPATIC PARASITES - BLOOD FLUKES

Schistosoma - Hepatic Schistosomiasis (Sherris 8e)

• Schistosoma mansoni: Inferior mesenteric veins → portal and descending colon veins → portal hypertension and liver fibrosis (most common cause worldwide)
• Schistosoma japonicum: Superior mesenteric vein → small intestine and ascending colon veins → also causes severe hepatic schistosomiasis
• Schistosoma haematobium: Bladder/pelvic veins → urinary schistosomiasis (not primarily hepatic)

• Unlike other trematodes: separate sexes (males + females)
• Male: 1-2 cm; deep ventral groove (gynecophoral canal / "schist") carries female in lifelong embrace
• Female: Longer, more slender; lives inside male's groove

1. Definitive hosts (humans, some mammals): Adult worms in mesenteric veins; mate → female deposits eggs (300-3000/day depending on species)
2. Eggs: Secreted enzymes digest surrounding tissue; eggs near mucosa rupture into gut/bladder lumen → pass in feces/urine
3. Freshwater snail (intermediate host): Eggs hatch → miracidia → penetrate snail → sporocysts → cercariae (bifurcate tail = furcocercariae)
4. Cercariae in water: Actively swim; penetrate human skin on contact → lose bifurcate tail → become schistosomulae → enter dermal capillaries → systemic circulation → pulmonary capillaries → heart → aorta → portal vein → liver → mature to adults → migrate to definitive site

• S. mansoni: Oval, 60 × 140 µm, prominent lateral spine
• S. japonicum: Round, 60 × 90 µm, small vestigial lateral knob (barely visible)
• S. haematobium: Oval, 115 × 65 µm, terminal spine (end spine)

1. Cercarial penetration (Swimmer's itch / Schistosome dermatitis):
   • Pruritic maculopapular rash at penetration site; lasts 24-48h
   • Due to hypersensitivity to cercarial antigens
2. Migration and maturation (Katayama fever):
   • 4-8 weeks after infection: acute serum sickness-like syndrome
   • Fever, urticaria, angioedema, marked eosinophilia, hepatosplenomegaly, lymphadenopathy
   • Immune complex deposition; especially with S. japonicum (higher egg output)
   • More severe with primary infections in non-immune individuals
3. Chronic egg deposition (Hepatosplenic schistosomiasis):
   • Eggs not excreted get trapped in tissues → eosinophilic granuloma formation (Splendore-Hoeppli reaction) around each egg
   • In the liver (portal tracts): Granulomas → fibrosis → periportal "pipestem" fibrosis (Symmers' clay-pipestem fibrosis) = pathognomonic of S. mansoni and S. japonicum
   • Progressive periportal fibrosis → portal hypertension with preserved hepatocyte function (pre-sinusoidal portal hypertension)
   • Liver surface: knobby, irregular
   • Hepatic function is RELATIVELY PRESERVED (pre-sinusoidal block) → jaundice and hepatic encephalopathy are late findings
   • Massive splenomegaly (most prominent feature; spleen may extend to pelvis)
   • Esophageal varices → GI hemorrhage = major cause of death
   • Secondary hypersplenism → pancytopenia

• Dense fibrous tissue deposited around portal vein branches (not around central veins)
• "Pipestem" = on cross-section, portal tracts look like pipe stems (thick fibrous wall around vessel)
• Contrast to alcoholic cirrhosis: hepatocyte architecture preserved; no nodule formation in early stages

• 200 million infected; 200,000 deaths/year → 2nd most important parasitic infection after malaria
• Distribution depends on snail host:
  • S. mansoni: Africa, Nile Delta, South America, Caribbean
  • S. japonicum: China, Philippines, Sulawesi
  • S. haematobium: Africa, Middle East

• Stool microscopy: Characteristic eggs (S. mansoni, S. japonicum)
• Urine microscopy: S. haematobium (terminal hematuria + terminal-spined eggs)
• Stool concentration techniques (Kato-Katz method)
• Serology (ELISA): Sensitive; useful for travelers who had low egg burden; stays positive for years
• Liver biopsy: Periportal fibrosis; granulomas with eggs
• Imaging: US = periportal echogenicity ("hyperechoic ring sign"); Doppler = portal hypertension

• Praziquantel: Drug of choice for all Schistosoma species
  • S. mansoni/haematobium: 40 mg/kg in 2 divided doses on 1 day
  • S. japonicum: 60 mg/kg in 3 divided doses on 1 day
  • Kills adult worms → prevents further egg deposition; some reversal of fibrosis if treated early

---

11. HEPATIC BACTERIA

Pyogenic Liver Abscess (PLA)

• Gram-negatives: Escherichia coli, Klebsiella pneumoniae (monomicrobial, especially in Southeast Asia/Taiwan = "primary Klebsiella liver abscess" syndrome - also causes metastatic endophthalmitis and meningitis)
• Anaerobes: Bacteroides fragilis, other Bacteroides spp., Peptostreptococcus
• Streptococcus milleri group (S. anginosus, S. intermedius, S. constellatus): Important cause; associated with metastatic spread to brain, lung
• Staphylococcus aureus: In immunocompromised, post-surgical
• Entamoeba histolytica: Amebic abscess (technically protozoa, see above)

• Portal vein (pylephlebitis): Appendicitis, diverticulitis, perforated viscus, IBD, bowel malignancy with necrosis → portal bacteremia
• Biliary tract (ascending cholangitis): Biliary obstruction (stones, strictures, malignancy) → bacterial colonization → ascending infection → liver abscess; accounts for ~40% (increasing with aging population + biliary manipulation)
• Direct extension: Subphrenic abscess, perinephric abscess, perforated gallbladder
• Hematogenous (hepatic artery): Systemic bacteremia (endocarditis, IV drug use)
• Cryptogenic: No identifiable source (~20% in some series)
• Post-procedure: After percutaneous biopsy, ERCP, ablation

• Predominantly in East/Southeast Asia; increasingly worldwide
• Specific hypervirulent capsular types (K1, K2) → resist phagocytosis
• Classic presentation: Primary Klebsiella liver abscess (no identifiable biliary source) in diabetics → metastatic spread to eye (endophthalmitis - often leading to blindness), CNS (meningitis, brain abscess), lungs
• hvKp (hypervirulent Klebsiella) carries hypermucoviscosity (positive string test: colony forms >5 mm string when stretched with loop)

---

12. HEPATITIS VIRUSES AND HCC - MOLECULAR MICROBIOLOGY SUMMARY

---

SUMMARY TABLE: HEPATIC INFECTIONS AT A GLANCE

---

---

• Pharmacology (antivirals for HBV/HCV/HDV, drugs for portal hypertension complications, UDCA, NAC)
• Medicine / Clinical Management (Harrison's 22e)
• Surgery (Schwartz/Sabiston/Bailey & Love)